Podcasts about Cancer Institute

A powerful rallying cry to protect the world's oceans has been issued from Sir David Attenborough.His message features in a new film, Ocean with David Attenborough, which opens in cinemas across the world today.Plus, Owkin has launched K Navigator, an AI-powered research co-pilot designed to revolutionise biomedical science.They say the technology is an “agentic playground” where researchers can explore, refine, and validate a theory, therefore accelerating the quality and pace of their discoveries.According to the Faculty of Pharmaceutical Medicine, it takes around 12 years for a laboratory discovery to become an approved medicine. There is also a high failure rate.Tech and Science Daily spoke to Dr Ingo Ringshausen, a consultant at University College London Hospital who runs a research group for the Cancer Institute and—importantly—was also one of the first to test the technology.Also in this episode:Could Nasa switch up and launch to Mars as early as 2026?London NHS worker awarded £29,000 after being likened to Darth VaderIs Scotland home to the world's oldest football pitch? Hosted on Acast. See acast.com/privacy for more information.

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Listen to the podcast here

Tom Cox, Vice President of Operations, and Tenille Oderwald, Director of Operations at OSF HealthCare Cancer Institute, discuss how advancements in brachytherapy and proton therapy are enhancing cancer care. They highlight the importance of thorough risk assessment processes for patients, the value of compassionate staff dedicated to patient needs, and the critical role of post-treatment care resources in improving outcomes.

Tom Cox, Vice President of Operations, and Tenille Oderwald, Director of Operations at OSF HealthCare Cancer Institute, discuss how advancements in brachytherapy and proton therapy are enhancing cancer care. They highlight the importance of thorough risk assessment processes for patients, the value of compassionate staff dedicated to patient needs, and the critical role of post-treatment care resources in improving outcomes.

Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Institute, discusses the continued recruitment of doctors and the strong support of team members as the clinic expands. He highlights progress in clinical and research efforts, along with strategies to support the team amid an influx of patients and the evolving impact of AI in healthcare.

Tune in this time to find out more about NSW's lead cancer control agency - Cancer Insitute NSW. We are joined by Prof Tracey O'Brien, Chief Cancer Officer to talk about her career to date and insights into CINSW's work across the state.

Virology vanguard Dr. Bob Gallo is far from ready to slow down. Now in his seventh decade as one of America's top scientists, he could easily sit back and enjoy the fruits of his numerous and pioneering achievements. His groundbreaking work began in the 1970s with research into human retroviruses, including the discovery of the T-cell growth factor (IL-2) and the identification of the Human T-Cell Lymphotropic Virus (HTLV-1) in 1980, earning him his first Lasker Award, often referred to as “America's Nobel Prize.” His subsequent research led to the identification of HIV-1 as the cause of AIDS, securing him a second Lasker Award. In the 1980s, he was the world's most cited scientist. Along with his team, he developed the first HIV blood test, crucial for understanding the spread of AIDS and managing HIV patients. In the mid 1990's Gallo and his collaborators discovered chemokines, naturally occurring compounds that were essential for understanding how HIV infects cells. Dr. Gallo later founded the Institute of Human Virology at the University of Maryland School of Medicine in 1996 and co-founded the Global Virus Network (GVN) in 2011 to enhance global virus detection and management. Recently, Dr. Gallo and his team moved to Tampa, the new global headquarters for GVN, where he now serves as director of the University of South Florida (USF) Virology Institute and Head of the Microbial Oncogenesis Program at the Cancer Institute at Tampa General Hospital (TGH).   In the first part of this wide-ranging interview, Dr. Gallo shares insights into his entry into virology and his initial research into the etiology of certain cancers. This work included crucial discoveries around T cell growth factors, paving the way for identifying HTLV-1. He discusses his collaboration with CDC epidemiologists, which led to recognizing AIDS as being caused by a retrovirus. Once the HIV virus was identified as the cause, creating the first blood test for HIV had profound impacts on the epidemic and patient care.   In the second segment, Dr. Gallo discusses the origins of the HIV virus and its early global spread. He also reflects on the COVID-19 pandemic, why the focus on its origins is irrelevant and reflects on how to rebuild public trust in science and medicine, which may have been damaged during the pandemic.   In the concluding segment, Dr. Gallo talks about his reasons for joining USF Health and TGH and the research areas he finds most promising going forward. He speculates on the prospects for an HIV vaccine, the impact of artificial intelligence on virology, and why he doesn't necessarily worry about the threat of the next global pandemic. Finally, Dr. Gallo opens up about how the early loss of his young sister deeply affected his life and his desired legacy. Dr Vega would like to thank her friend Job Meiller, her YES Man, for the wonderful musical contributions and coming through on every idea she has. This time he contributes his renditions of Bruce Springsteen's "Streets of Philadelphia" and "Your Song," by Elton John. Thank you Job! Thanks also to Dr. Ana Velez, our artistic contributor, for her painting, "HIV," used in our episode thumbnail.

In this episode, Dr. Boris C. Pasche, President and CEO at Karmanos Cancer Institute, delves into the latest advances in cancer treatment. He highlights exciting developments in theranostics, immunotherapy, and radiofrequency technologies, offering new hope for patients with advanced cancer. Dr. Pasche shares insights on how these therapies are transforming the future of oncology and improving patient outcomes.

For more information about Hamilton Health Care System's imaging services, visit HamiltonHealth.com/imaging. To make an appointment for imaging at Hamilton Diagnostics Center or a mammogram at People's Cancer Institute, call 706-272-6565. To learn more about Peeples Cancer Institute, visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Para obtener más información sobre los servicios de imágenes de Hamilton Health Care System, visite HamiltonHealth.com/imaging. Para programar una cita para imágenes en Hamilton Diagnostics Center o una mamografía en People's Cancer Institute, llame al 706-272-6565. Para obtener más información sobre Peeples Cancer Institute, visite HamiltonHealth.com/cancer.Este programa de ninguna manera busca diagnosticar o tratar enfermedades ni reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud.

A website for the Prostate Cancer Institute of America:   www.prostatecancerusa.comDr, Ajay Bhatnagar: (33) Ajay Bhatnagar MD,MBA | LinkedIn A recent publication from our guest, Dr. Bhatnagar:Modern Low Dose Rate Brachytherapy For Prostate Cancer: A Comprehensive Guide for Urologists: Bhatnagar, Dr. Ajay, Koneru, Dr. Bobby N., Agarwal, Dr. Manuj, Wallner, Dr. Kent, Patel, Dr. Pratik: 9798338512012: Amazon.com: Books

In this episode, Dr. Aaron Spalding, Executive Medical Director at Norton Cancer Institute, discusses innovations in cancer care, the importance of coordinated care teams, and the future of early cancer detection. He also shares insights on leadership in healthcare, emphasizing the value of empathy and listening in both patient care and leadership roles.

In this episode, Laura Matthews, Vice President and Administrator at Inova Schar Cancer Institute, reflects on the institute's five-year milestone. She discusses the institute's rapid growth, the importance of maintaining patient access, and the innovative programs focused on cancer prevention and psychosocial support.

Ann Barshinger passed away at 100 years old, and leaves behind a lasting impact on the people she's served in Central Pennsylvania. Barshinger was known for her big heart and generosity. Over the years, she's donated millions to hospitals, colleges, churches, and many more organizations. Ann was also instrumental in the opening of Ann B. Barshinger Cancer Institute, part of Penn Medicine Lancaster General Health in 2013. Dr. Randall A. Oyer a founding executive medical director of the Ann B. Barshinger Cancer Institute said cancer never touched her family, but wanted to provide support to the families that we impacted by cancer. "People often ask Ann if she had cancer or if someone in her family had had cancer, and she said no. She had simply seen and felt the strain, the stress, the suffering that friends, or others that she knew had to deal with when they, faced the cancer diagnosis and she wanted to make sure that all cancer care was convenient with close to home, that people had better chances of being cured, and that people were treated like human beings, in their cancer treatment, "said Dr. Oyer. Megan Tomsheck is the Senior Vice President and Chief Development Officer with Vision Corps. Tomsheck has known Ann for 10 years says she lived to give, and her legacy will live on for generations to come. " So many times we'd be out having breakfast and somebody would come up and thank her for her support of the Cancer Institute, because they recognized her, because they had a family member who received services. So, it just to watch her little spark go throughout the community. And the ripple effect was was amazing to watch something I'll always be thankful for the opportunity to to be part of, "said Tomsheck. WITF was also a beneficiary of Ann's generosity. She had been a donor for over 20 years, and her foundation supported stipends for interns from York County, among other things.      Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Dr. Lisa Duhaime is a board-certified medical oncologist at Peeples Cancer Institute in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

La Dra. Lisa Duhaime es oncóloga médica certificada por la junta del Peeples Cancer Institute en Dalton, Georgia.Para obtener más información sobre Peeples Cancer Institute, llame al 844-PCI-HOPE o visite HamiltonHealth.com/cancer.Este podcast de ninguna manera busca diagnosticar o tratar enfermedades o reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud. La versión en español es una traducción del original en inglés. En caso de discrepancia, prevalecerá el original en inglés (Health for Life: https://health-for-life.captivate.fm/listen).This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem. The Spanish version is a translation of the original in English. In case of a discrepancy, the English original (Health for Life: https://health-for-life.captivate.fm/listen) will prevail.

Dr. Shannon Westin and her guest, Dr. Chao Cao, discuss the paper "Prevalence and Cancer-Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022" recently published in the JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare.  Dr. Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth with authors and manuscripts that have been published in the Journal of Clinical Oncology. I'm your host, Shannon Westin, gynecologic oncologist by trade and Social Media Editor for the JCO. And it is my pleasure to welcome Dr. Cao, a research fellow in medicine, Department of Medical Oncology, Dana Farber, Cancer Institute, Boston, Massachusetts. Welcome. Dr. Cao: Thanks for having me. Dr. Shannon Westin: Of course. And we're going to be discussing your very important work, “The Prevalence and Cancer Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022,” which was published in the Journal of Clinical Oncology on April 4, 2024. And Dr. Cao has no conflicts of interest in regards to this podcast.  So let's get right into it. I'd love to level set. Can you speak a little bit about the definition of cancer survivorship and the number of cancer survivors currently in the United States?  Dr. Cao: I think this is an important question because everyone somewhat has confusion about the definition of cancer survivorship. So based on the definition by the National Cancer Institute, cancer survivorship refers to the phase of life following the diagnosed cancer. And nowadays, it's estimated about 80 million American individuals are living after being diagnosed with cancer. And this number is projected to rise to 26 million by 2040. Dr. Shannon Westin: Wow. So obviously, any research that we can do in this population is going to be so important as that number absolutely continues to grow.  And before we get into the specifics of your work, I'd love for you to speak a little bit about the importance of functional disability, which is what we studied in this work and why it might be observed in cancer survivors.  Dr. Cao: Yeah, sure. So, maintaining physical function is fundamental to perform life tasks and engage in fruitful jobs. In terms of cancer survivors, many cancer survivors experience side effects from cancer and its treatment. These side effects, include the pain, fatigue, and musculoskeletal dysfunction, which can induce physical limitation and eventually physical disability. And specifically, this is such a burden for the US, social, societal and economic burden. Here I have the specific number: so in 2019, an estimate of over 100,000 people living with and beyond cancer were unable to work and they received a Social Security Administration disability benefit with the resulting cost of US$1.8 billion in disability claims. Dr. Shannon Westin: Wow. We always think about the impact on the survivor, on their family, but I think it's also really important to look at those other objective data about the impact on society as a whole. Thank you, that was great detail.   Do we know anything about who might be proportionately more affected by cancer induced physical impairments and disabilities? Dr. Cao: Actually, this is our key question for our manuscript, but before we developed our hypothesis, we also looked at the data from the general population. So we observed that visual minorities and underserved populations, such as people with lower socioeconomic status and living in the rural area, and also those with unhealthy types of behavior, for example, smoking, obesity, and physical inactivity, are more likely to have physical limitations and disabilities. And also the comorbidity in cancer survival, such as diabetes, cardiovascular disease, also increase the likelihood of physical disability. We also have cancer survivors, particularly for cancer patients who are currently receiving cancer treatment, for example, chemotherapy and radiation therapy, they also are more likely to report side effects from the treatment, also have the reduced physical function. So we also think the cancer patients during the treatment also have a higher likely chance to have physical disability. Dr. Shannon Westin: Absolutely. That makes sense, and that really dovetails nicely into the objective of your study. We'd love for you to briefly summarize your objective and the methods you employed to achieve that goal.  Dr. Cao: Yeah, sure. We used the six-year data, 2017 to 2022 from the Behavioral Risk Factor Surveillance System to investigate problems and factors of functional disability in over 47,000 cancer survivors and 2.4 million adults without cancer diagnosis aged 80 years and older. And we specifically focused on two types of functional disability. The first one is mobility disability, which is defined as self reported severe difficulty walking or climbing stairs. And also another one is self care disability, which is defined as self reported difficulty dressing or bathing. And also we examined the factors, for example, social demographic characteristics, lapse of behavior, and health related factors, and some cancer related factors, how these factors related to the functional disability. Dr. Shannon Westin: Okay, great. So before we get into your findings, I'd love to hear just a little bit more about the BRFSS, the Behavioral Risk Factor Surveillance System. Why did you choose data from this survey for your study?  Dr. Cao: This is a very key question, because nowadays there are no specific cohort studies for cancer survivors. And also actually, in the population based study, there is no field data specifically for the cancer survivor. But fortunately, in the United States, the CDC conducted several nationally representative surveys to examine the health status of the people living in the United States. So we used the data from the Behavioral Risk Factor Survival System, we also called BRFSS. So BRFSS is a nationwide telephone based survey conducted by the CDC and it collects information on health related risk factors and chronic micro conditions among the US adults aged 80 years or older. And specifically for our papers, because recently, the BRFSS also added a section on the cancer survivorship, which included a lot of the variables on cancer, diagnosed cancer type, and also cancer related factor symptoms, for example, the cancer or cancer treatment related pain. So we used this data to realize our idea.  Dr. Shannon Westin: Okay, great. So let's start with what you found in regards to the first aspect with mobility disability.  Dr. Cao: First, we observed the problems of mobility stability are much higher in cancer survivors than non-cancer adults. And also among cancer survivors, more than 25% of cancer survivors reported mobility disability. We also observe the prevalence of mobility disability is much higher in racial minority groups and underserved populations and those with unhealthy behavior and medical conditions. Dr. Shannon Westin: In addition to the underrepresented minorities, were there any other kind of socioeconomic, demographic factors associated with high prevalence of mobility disability? Dr. Cao: Yes, the factors like lower level of education, income, being unmarried, and living in non metropolitan areas were associated with higher prevalence of mobility disability. And also, I forgot to mention another factor is cancer related factors. We're also including several cancer related factors such as cancer and cancer related pain. So we also observed a higher prevalence of the mobility disability in people, in cancer survivors with cancer and cancer related pain. We also see the prevalence of the mobility disability is much higher in the patients who are currently receiving the cancer treatment than those who already completed the cancer treatment. Dr. Shannon Westin: Yeah, that makes a lot of sense. And to that end, with regards to treatment, were there any cancer specific patterns of mobility disability? Dr. Cao: Yeah, and also, I think this is another strength of our study, because the BRFSS high sample size, which clearly evaluates the mobility disability in over 47,000 cancer survivors,  which allowed us to do the cancer specific part of mobility disability. We observed that the survivors of lung cancer and brain cancer and bone cancer have the highest prevalence of mobility disability. And interestingly, we also observed that the women with cancers also had, for example, ovary, cervical cancer survivors also have higher problems of mobility disability. Probably you know, better than me, and I just tell the data. Dr. Shannon Westin: Well, it's interesting, I was thinking, it seems like we have a lot, but I have no, obviously, frame of reference with other cancer types. So it's intriguing to me that that's definitely what we see in our clinic. So I'm intrigued to understand more about this.  But before we get into the next steps and that type of thing, I do want to make sure we touch on that other aspect that you looked at, the self care disability and give the listeners a little bit of an idea of what you found there?  Dr. Cao: The self care disability is kind of the more severe of the functional disability, which means, we say candidates, lower prevalence compared to the mobility disability, but still the patterns or factors associated with self care disability are much similar with mobility disability. An interesting finding is that in terms of the mobility disability, we find that older survivors are more likely to report mobility disability than younger survivors. In contrast, in terms of the self care disability, younger survivors are more likely to report than the older cancer survivors.  Dr. Shannon Westin: You've touched a little bit on some of the socioeconomic and demographic factors that were different with self care disability. Was there anything else that really caught your eye? Cancer specific factors or anything else like that? Dr. Cao: Yeah, besides this, I think also we observe that women are more likely to report self care disability. I think also this is driven by the cancer specific, particularly the woman cancers have a higher prevalence of the self care disability. Dr. Shannon Westin: Well, it's definitely something for me to take back to my clinic. Now that you've covered all these results, how are your data compared to existing literature in this area?  Dr. Cao: Yeah, we have tended to do comprehensive literature reviews. When we discuss our results and compare it with existing literature, our result is quite aligned with previous literature and particularly we clearly see the racial ethnic minority have a higher prevalence of physical limitation and physical function decline. But our paper focused on the physical disability which is much more severe than the physical function. And also we also looked at another study conducted in Australia, we quite find very similar results even for cancer specific patterns of the functional disability.  Dr. Shannon Westin: I guess the next question I have is was there anything that surprised you about your results?  Dr. Cao: I just mentioned that what surprised me the most is that the older people are more likely to report the mobility disability, but the younger people are more likely to report self care disability. Our data don't support or explore why this happened and what's the etiology behind this. But our hypothesis is that the younger cancer survivor, younger cancer patients are more likely to receive the aggressive treatment that can play a significant role in the functional outcome.  Dr. Shannon Westin: Yeah, it sounds like that's definitely an area of unmet need for more research. But I like your hypothesis. I do wonder if that's somewhat related.   And I guess that leads us to our final question. What are your next steps and how can I potentially use this in practice? How can our listeners employ these findings in their practice? What do you recommend? Dr. Cao: I think our findings highlight the importance of screening for functional limitations at the baseline and throughout the cancer treatment and even the cancer survivorship. Oncology providers also should encourage patients to be physically active. And also American Society of Clinical Oncology and also American College of Sports Medicine recommend that regular exercise during the treatment can help cancer patients preserve their fitness and reduce the incidence and the severity of the cancer related disability. And also providers can provide referral to rehabilitation services and support groups for additional care.  For the next step, our finding highlights the importance of developing ways to limit the long term side effects of cancer treatment both during and after treatment to preserve fixed function and prevent disability. Particularly, target intervention should in particular address special needs in vulnerable populations, including the racial ethnic minorities and those living in the rural areas to improve their quality of life during a long term survivorship. And also due to the advance in the technologies, now we want to see whether wearable sensors, wearable devices can be a novel tool to monitor their physical functions during the treatment because better monitors can lead into their better treatment and their prevention. Dr. Shannon Westin: That's great. Yeah, what a great way to end. I think that exercise clearly is key not only for preventing these issues, but also we know that it potentially can even improve response to therapy and recurrence free survival. So I think lots of reasons to be focusing on physical activity in our clinics and ensuring our patients and our cancer survivors are really participating in those types of activities.  Well, Dr. Cao, it was such a pleasure. I cannot believe you are only a research fellow. I can't wait to see where your career takes you. Congratulations on this great work. Dr. Cao: Thank you. Thank you for this great opportunity to share my work and I look forward for my future work in the field. Dr. Shannon Westin: Oh, yeah. So you guys, if you're looking for somebody to come and push the boundaries of functional disability and activity, you know where to look.  And again, thank you all our listeners for tuning in to another episode of JCO After Hours. Again, we were discussing, “The Prevalence and Cancer Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022.” Original research published in the JCO, April 4th, 2024. So if you're looking for more podcast offerings, check out other JCO After Hours offerings wherever you get your podcasts. Have an awesome day.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

In this episode, Kip Lee, VP of Innovation & Product Strategy, University Hospitals, Brian Kovach, Vice President, Cancer Institute, MetroHealth, & Joseph Rich, Senior Director, Cleveland Clinic Innovations, all share insights into the focus and future of The Cleveland Innovation District from their perspective roles.

In this episode, Kip Lee, VP of Innovation & Product Strategy, University Hospitals, Brian Kovach, Vice President, Cancer Institute, MetroHealth, & Joseph Rich, Senior Director, Cleveland Clinic Innovations, all share insights into the focus and future of The Cleveland Innovation District from their perspective roles.

In this episode, Dr. John Deeken, President at Inova Schar Cancer Institute shares insights into his background, what trends & issues in healthcare he is keeping a close eye on, what traits the most effective healthcare leaders will need to be successful in the coming years, and more.

Dr. Guru Sonpavde, Medical Director of Genitourinary Oncology (GU), AdventHealth Cancer Institute joins the podcast to dive deep into some of the clinical research that AdventHealth is pioneering and the work around a new bladder cancer therapy vaccine that represents the forefront of precision oncology.

In this episode, Dr. Wassim McHayleh, Clinical Program Director for the Breast Cancer Program, AdventHealth Cancer Institute shares insights into his background, AdventHealth's Breast Multidisciplinary (MCD) Model, how the model benefits both patients and providers, advice for other systems adopting this model, and more.

In this episode, Daniel Arnold sits down with Dianne Keen, a healthcare education and marketing specialist with over 25 years of experience in Radiology Practice Development. Dianne shares her unexpected entry into radiology and her pivotal role in promoting interventional radiology (IR) procedures. After serving as the Director of Practice Development & Strategic Initiatives at Radiology Partners, she takes on the role of Vice President of Strategy and Growth for Abbadox, a healthcare software provider specializing in Radiology workflow solutions. Dianne emphasizes the importance of understanding the clinical side, building trust with referring physicians, and advocating for women's imaging. Dianne shares her experiences in scaling radiology programs, fostering relationships with gynecologists, and ensuring breast care programs are integral to the growing Cancer Institute. Dianne also discusses her transition to Abbadox, highlighting the company's mission to improve the work lives of healthcare professionals through integrated workflow solutions. The conversation concludes with insights into the future of healthcare and radiology, emphasizing the need to adapt to technological advancements, streamline processes, and maintain a strong commitment to patient care.

As part of our Let's Finish Cancer series, Mary Renouf speaks with Dr. Melanie Goldfarb, a fellowship-trained endocrine surgeon and oncologist specializing in minimal access surgery for thyroid, parathyroid and adrenal tumors and one of the first physicians on the west coast to offer radio-frequency ablation of thyroid nodules. They discuss thyroid nodules, thyroid cancer and its different treatments.For more information and resources, visit: Providence at ⁠providence.org⁠Provience Saint John's Cancer Institute at ⁠saintjohnscancer.orgAnd to listen and subscribe to our Let's Finish Cancer series here: 

"Finding out the patient is high-risk after they are diagnosed with cancer is too late," says Dr. Eric Brown, surgical oncologist and breast multidisciplinary team co-lead.

Today's guest is Dr. Faraz Harsini. He's a cultivated meat bioprocessing scientist at the Good Food Institute and the founder and CEO of Allied Scholars for Animal Protection – a nonprofit that supports and mentors student advocates and future vegan leaders for the abolition of cruelty to humans and nonhumans. Dr. Harsini appeared on the podcast in episode 256, in which we discussed his upbringing in Iran as a member of the LGBT community, his advocacy work on college campuses, and a myriad of social justice issues, but the conversation was so powerful, and there was so much ground we didn't get to cover, especially about his current work, that we had to have him back.    So whether or not you listened to the first part of our interview with him, you definitely want to stay with us as we tackle some serious topical issues that pertain to everyone.   “I guess the reason that I promote a plant-based diet and veganism full-time today is because I did my entire master's on cancer, and I worked on proteins involving cancer. And the fact that nobody ever mentioned diet at all, like I'm not talking about my research, no one, even those textbooks. And it had to come as a surprise to me when I like had to learn it by myself, and then you looked at it and you realized that every single Cancer Institute in the world says the less meat you eat, the better. Every single Cancer Institute in the world, and some even include Dairy and other types of meat, but when it comes to processed and unprocessed red meat, every single Cancer Institute in the world says the less meat you eat, the better.” - Dr. Faraz Harsini   What we discuss in this episode: - The complete protein myth and why plants are such a powerful source of protein. - What happens when you cook and eat red meat? - The benefits of cultivated meat production. - The dangers posed to humans from animal experimentation. - The cruelty Dr. Harsini witnessed while visiting a dairy farm in Texas. - Dr. Harsini's thoughts on changing our food system. - The importance of speaking up as a vegan.   Resources: - Dr. Harsini's website: Dr. Faraz Harsini - ASAP's website: Allied Scholars for Animal Protection - Good Food Institute: Faraz Harsini, M.Sc., Ph.D. - The Good Food Institute - Dr. Harsini's Instagram: Dr. Faraz Harsini (@dr_faraz_harsini) • Instagram photos and videos - Twitter: https://twitter.com/DrFarazHarsini - YouTube: Dr. Faraz Harsini - YouTube - Animal Activism Mentorship - https://animalactivismmentorship.com/   ★☆★ Click the link below to support the ADD SOY Act! ★☆★ https://switch4good.org/add-soy-act/ ★☆★ Share the website and get your resources here ★☆★ https://kidsandmilk.org/ ★☆★ Send us a voice message and ask a question. We want to hear from you! ★☆★ https://switch4good.org/podcast/ ★☆★ Dairy-Free Swaps Guide: Easy Anti-Inflammatory Meals, Recipes, and Tips ★☆★ https://switch4good.org/dairy-free-swaps-guide ★☆★SUPPORT SWITCH4GOOD★☆★ https://switch4good.org/support-us/ ★☆★ JOIN OUR PRIVATE FACEBOOK GROUP ★☆★  https://www.facebook.com/groups/podcastchat ★☆★ SWITCH4GOOD WEBSITE ★☆★ https://switch4good.org/ ★☆★ ONLINE STORE ★☆★ https://shop.switch4good.org/shop/ ★☆★ FOLLOW US ON INSTAGRAM ★☆★ https://www.instagram.com/Switch4Good/ ★☆★ LIKE US ON FACEBOOK ★☆★ https://www.facebook.com/Switch4Good/ ★☆★ FOLLOW US ON TWITTER ★☆★ https://mobile.twitter.com/Switch4GoodNFT ★☆★ AMAZON STORE ★☆★ https://www.amazon.com/shop/switch4good ★☆★ DOWNLOAD THE ABILLION APP ★☆★ https://app.abillion.com/users/switch4good

In this week's episode, Dr. Boris Pasche, president and CEO of Karmanos Cancer Institute, joins HealthLeaders strategy editor Jay Asser to talk about his vision for the organization and cancer care. Pasche, who took on the role in August, also offers insight on navigating workforce challenges and improving physician relations, while forecasting some of healthcare's biggest obstacles in 2024.

Lecia Bushak speaks with Ysabel Duron, founder and executive director of the Latino Cancer Institute, about health equity, especially in the Latinx community, as well as her career spanning from healthcare association leader to award-winning journalist. Follow us: @mmmnewsTo read more of the most timely, balanced and original reporting in medical marketing, subscribe here. Music by Sixième Son.Follow us: @mmmnewsTo read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely prescribed drug venetoclax, according to a recent study published in Cancer Discovery and led by scientists from Perlmutter Cancer Center at NYU Langone Health. Today on OncTimes Talk, we interview Dr. Christina Glytsou, lead author of the study, and discuss the reasons behind leukemia cells’ resistance to venetoclax, a BH3 mimetic drug that promotes cancer cell death in individuals with AML. Dr. Glytsou holds a joint appointment as an Assistant Professor in the Department of Chemical Biology at the Ernest Mario School of Pharmacy of Rutgers University and the Department of Pediatrics at Rutgers Robert Wood Johnson Medical School. She is a member of Cancer Metabolism & Immunology and the Cancer Pharmacology Programs, at the Cancer Institute of New Jersey. Dr. Glytsou’s laboratory aims to address fundamental questions unravelling the role of mitochondrial biology in blood malignancies’ progression and drug resistance.

Dr. Howard Edington, a  surgical oncologist with AHN's Cancer Institute joins to discuss AHN opening the new Skin Cancer Center at West Penn Hospital. 

Dr. Lisa Duhaime is a board-certified medical oncologist at Peeples Cancer Institute in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

La Dra. Lisa Duhaime es oncóloga médica certificada por la junta del Peeples Cancer Institute en Dalton, Georgia.Para obtener más información sobre Peeples Cancer Institute, llame al 844-PCI-HOPE o visite HamiltonHealth.com/cancer.Este podcast de ninguna manera busca diagnosticar o tratar enfermedades o reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud. La versión en español es una traducción del original en inglés. En caso de discrepancia, prevalecerá el original en inglés (Health for Life: https://health-for-life.captivate.fm/listen).This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem. The Spanish version is a translation of the original in English. In case of a discrepancy, the English original (Health for Life: https://health-for-life.captivate.fm/listen) will prevail.

Christina Curtis is a Professor of Medicine and the Director of Artificial Intelligence and Cancer Genomics at Stanford University's Cancer Institute. Among her many achievements is the conception of the “Big Bang Theory” of tumor biology. In this episode, she tells us how not being biased by assumptions of what we know has been very helpful in her research. We talk about how her background in statistical genetics has shaped her cancer research. We also discuss how the despair of not understanding is a phase that occurs in almost any research project, and we discuss the use of generative AI in the creative scientific process. For more information on Night Science, visit https://www.biomedcentral.com/collections/night-science .

In this episode, Dr. Mistry and Donna Lee are joined by Dr. Paiman Ghafoori of the Texas Cancer Institute. Dr. Ghafoori is a radiation oncologist who specializes in the use of radiation treatments for all kinds of cancer. He says the best candidates for radiation therapy  are those with high-risk cancers  in which surgery is the primary treatment, but additional treatments may be necessary. Although focused radiation treatments are noninvasive, complications may include urinary irritation/bladder symptoms, radiation proctitis, decreased sexual function. Fortunately, these side effects can be managed with your  If you'd like to learn more about cancer treatment, give Dr. Ghafoori a call or visit him online today!Voted top Men's Health Podcast, Sex Therapy Podcast, and Prostate Cancer Podcast by FeedSpotDr. Mistry is a board-certified urologist and has been treating patients in the Austin and Greater Williamson County area since he started his private practice in 2007.We enjoy hearing from you! Email us at armormenshealth@gmail.com and we'll answer your question in an upcoming episode.Phone: (512) 238-0762Email: Armormenshealth@gmail.comWebsite: Armormenshealth.comOur Locations:Round Rock Office970 Hester's Crossing RoadSuite 101Round Rock, TX 78681South Austin Office6501 South CongressSuite 1-103Austin, TX 78745Lakeline Office12505 Hymeadow DriveSuite 2CAustin, TX 78750Dripping Springs Office170 Benney LaneSuite 202Dripping Springs, TX 78620

This episode features Dr. Mohamedtaki Tejani the Medical Director of the Gastrointestinal Oncology Program at the AdventHealth Cancer Institute in Orlando, & Dr. Amber Orman, a Radiation Oncologist and Board-Certified Lifestyle Medicine Specialist at AdventHealth Celebration. Here, they discuss a new study recently published in JAMA that shows breast, colon and pancreatic cancer rates increasing at concerning rates among America's young adults, why they believe this trend of seeing younger patients is happening, how lifestyle plays into higher rates, what can be done to decrease risk, and more.

In this JCO Article Insights episode, Emily Zabor interviews Dr. Gregory H. Reaman, the Scientific Director of the Childhood Cancer Data Initiative at the National Cancer Institute, on their paper titled  “The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer”. Dr. Reaman introduces us to the initiative, its goals and structure, and what has already been achieved since its launch. TRANSCRIPT The guest on this podcast episode has no disclosures to declare.  Emily Zabor: Welcome to this JCO Article Insights episode for the August issue of JCO. This is Emily Zabor, JCO's Biostatistics Editorial Fellow. And today I am interviewing Dr. Gregory Reaman, the Scientific Director of the Childhood Cancer Data Initiative at the National Cancer Institute, on their paper titled “The Childhood Cancer Data Initiative: Using the Power of Data to Learn from and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer.” Dr. Reaman, welcome to our podcast. Dr. Gregory Reaman: Thanks very much, Emily. Appreciate the invitation. Emily Zabor: Dr. Reaman, could you start by introducing yourself and describing your involvement in the Childhood Cancer Data Initiative? Dr. Gregory Reaman: I'm Gregory Reaman. I'm a Pediatric Oncologist. And I guess my involvement with the CCDI began shortly after the initiative was announced at the State of the Union media address in 2019, which was followed shortly thereafter by the formation of a working group by the NCI's National Cancer Advisory Board Board of Scientific Advisors. Given my role at the FDA at that time as Associate Director for Pediatric Oncology in the Oncology Center of Excellence, and the fact that I was the founding Chair of the Children's Oncology Group, I was an ex-officio member of this working group. So from very early on, I had involvement. I formally joined the NCI in November, left the FDA to assume the position as Scientific Director of CCDI. Emily Zabor: That's great. So you've really been involved from the start. I had not really been familiar with the initiative until I read this paper. And as a cancer biostatistician, I was really excited to learn about this initiative, which sounds like it will ultimately create a very valuable data resource to be used for research purposes, among other things. So I think it's a really interesting project. So for our listeners who may not be familiar, could you describe the motivation for and goals of the Childhood Cancer Data Initiative? Dr. Gregory Reaman: As I mentioned, this really is a very unique initiative, venture, if you will, on the part of the Cancer Institute and in large part driven by this fortunate infusion of funds to support childhood cancer research. And given the fact that pediatric oncology is very much a collaborative enterprise, it really does sort of follow that data sharing and using the power of data, its ability to be used by multiple investigators, irrespective of the source, aspirationally can improve outcomes for children cancer. The three primary objectives– actually, this working group that I mentioned earlier put together a white paper that had 24 specific recommendations to the NCI. But there were three foundational objectives or goals. One was to learn from every child diagnosed with cancer, irrespective of the institution where they were diagnosed to receive therapy, to develop an ecosystem that would enable the submission, aggregation of data, and harmonization in a federated system that could then be accessed and used by investigators and analyzed to ultimately improve outcomes. And then one objective, which was a little bit more specific, and that was to really focus on the opportunity to genomically classify tumors from newly diagnosed pediatric cancer patients, because this was something that obviously is much more widespread in the adult population, given the advent of targeted therapy and precision oncology and its more widespread use in medical oncology than pediatrics. And although many large academic institutions do have resources, the majority of smaller institutions do not. And when it's necessary and preferable to accurately and timely identify or diagnose a child's cancer that may actually provide information on treatment recommendations, the ability to do that and have it covered by insurance is sometimes problematic. So developing a program that would not cost patients or institutions anything and then make that data available to patients, families, and providers, as well as making it available for secondary research use, was a major goal and objective. Emily Zabor: Yeah, that sounds like such an important initiative. The Molecular Characterization Initiative, which I understand has already enrolled and characterized the genomics of 751 participants just in the first year, I think is what the paper reported? Dr. Gregory Reaman: That's correct. That was in the first year. We're now beyond the first year and we're approaching 2000 patients that have had their tumors genotyped and about 1500 results that have been returned to patients and providers. Emily Zabor: That's fantastic. So with this linkage to the clinical data, that's going to be an extremely important data source. And I understand that the participation is currently limited to members of the Children's Oncology Group, which consists of over 200 children's hospitals, universities, and cancer centers. Can you describe in more detail what information it currently provides and how this initiative is going to be advertised and implemented to ensure complete participation across all of these member sites? Because that sounds like a really big challenge. Dr. Gregory Reaman: Limiting the participation to the Children's Oncology Group initially was in no way meant to be exclusionary, but really provided an opportunity for linkage to clinical data. Since the Children's Oncology Group really represents nearly all of the pediatric cancer programs in the United States and some programs even outside the US, in Canada, and a couple of European sites, Australia and New Zealand, it was felt that given the resources that currently exist within the COG for specimen procurement, specimen submission, and then DNA and RNA extraction through the COG's Biopathology Center at the Nationwide Children's Hospital would really facilitate having the sequencing done at a single site, single institution, using a single platform. And also it provided an opportunity for some clinical data, including demographics, diagnosis, radiographic data, and treatment data that could be collected somewhat longitudinally from patients enrolled on the MCI. Looking to make this as broad as possible since the objective of the CCDI is to learn from every patient, and every patient that we're concerned about not being able to capture adequately within the Children's Oncology Group are older adolescents and young adults with cancers that are more frequently seen in the pediatric population. So we are looking at ways to work with the COG's Biopathology Center to see if we can create systems that we can actually have specimens submitted from patients seen at institutions outside of the COG and molecularly characterized the same way. And that will be important as we launch another new planned initiative called the Coordinated National Initiative for the Treatment of Rare Pediatric and Young Adult Cancers. Emily Zabor: Okay, that makes sense. So those adolescents and young adults are harder to capture since they're not being seen at those COG member institutions. Okay, well, that sounds like a big challenge to find those patients at their institutions and get them involved, but I think it's an important piece of this for sure. Dr. Gregory Reaman: I should also point out that there were opportunities for some of the larger well, for all of the NCI-designated cancer centers, the pediatric programs associated with those cancer centers, to submit genomic data on newly diagnosed patients. That was something that actually transpired early on in the history of CCDI. So those data are in the CCDI's ecosystem. Emily Zabor: Oh, that's great. So you collected the existing data. Dr. Gregory Reaman: Right.  Emily Zabor: That kind of leads into my next question about aggregating data sources. With these disparate sources of pediatric cancer data, it seems like the aggregation is a lofty and important goal, but once that's complete, you're going to have this data ecosystem, which you said was one of the main goals of this initiative. I was wondering if you could tell us who will have access to this data ecosystem and what will be required for individuals to gain access. Dr. Gregory Reaman: All of CCDI was predicated on this really being a community initiative if you will, so multidisciplinary and community-based. So patients, families, advocates, clinical researchers, physician providers, basic and translational researchers, researchers in public health and epidemiology. So there will be different levels of data that will be available to specific individuals. Patient-level data will be deidentified through a system of APIs that will be used that will enable the association of clinical data to existing molecular data and outcome data that might be available in the ecosystem. Those data will be- there are many data in the ecosystem that will be open source and available to anyone who is interested. This includes data from the NCCR in the Childhood Cancer Data Catalog, which is basically a listing of some close to 300 pediatric cancer databases that are available. The patient-level data will be sort of a controlled access. So there will be a requirement for individuals, investigators who wish to access that data, to sort of be certified, if you will, utilizing NCI and NIH data sharing requirements. Emily Zabor: That makes sense. Yeah, you mentioned deidentification, but especially when we're dealing with these kinds of rare diseases, patient privacy does seem like it could be a concern. So what exactly are you doing to ensure that that is not something that gets violated through this process? Dr. Gregory Reaman: I think there's every attempt to eliminate any PPI, HPI, obviously. So, again, most of the clinical data that are being provided currently are data that's coming from the Children's Oncology Group, where for every patient enrolled or registered through the COG and enrolled on a clinical trial, there is a COG ID number that is associated and that will be available only to the NCI and the CCDI to link it to unique specimen identification numbers, which are the only numbers that will be available to any investigator. So no one will be able to make the connection from the specimen identifier to the unique patient identifier in the COG. Emily Zabor: That's great. And that way, you can really get access to all of the detailed data without concerns about privacy. Dr. Gregory Reaman: Correct. And then being able to link all of these disparate data sets will really require the identification or the development, I should say, of a participant index. So that is one of our highest priorities right now in developing a CCDI participant index so that we would be able to link the identifier or clinical data with any research data or biologic data that may be available on patients to facilitate research plans and programs. Emily Zabor: And through that process, is there also some method involved for identifying duplicated data? Because I assume some of these patients may get seen at different institutions over time, and that could be a concern that they end up in the database multiple times. Dr. Gregory Reaman: That's exactly why I think developing the participant index is so critical to, number one, link, and number two, to avoid, prevent duplication, because you're absolutely right. There may well be the same patient data in multiple data sets, which are, of course, disparate. And the only way that they're going to be really utilizable and made interoperable is by linking them to the specific patient or individual patient. Emily Zabor: Great. And do you have an idea of the timeline when that part would be complete and this data ecosystem would be available to researchers?  Dr. Gregory Reaman: The ecosystem is already available to researchers. We launched several months ago the CCDI hub, which is sort of the entryway or entry point, if you will, for access to the ecosystem. We hope to actually have the participant index up and running, and it's something that we've been working on for over a year, but actually available and utilizable within the next several months.  Emily Zabor: That's fantastic. We'll have to go check out the CCDI hub that's already out there then. Before we end, is there anything you'd like to share with our listeners that we haven't already discussed? Dr. Gregory Reaman: Well, I think the one program that I mentioned just briefly, the Coordinated National Initiative for Rare Pediatric and Young Adult Cancers, we see there's a real opportunity to address a major unmet need. Fortunately, all pediatric cancer is rare, but there are some cancers that are extremely rare and for which there are, in many cases, no defining standard of care, and in many cases, there are no treatment protocols because of the difficulty mounting studies with such small patient numbers. So we see this as an opportunity to actually develop a registry that will provide, hopefully, natural history data that will inform clinical trials. All of these patients will be enrolled on the Molecular Characterization Initiative. So there will be the opportunity to hopefully learn if there are specific molecular drivers of some of these cancers that could inform the use of targeted drugs in a therapeutic approach to some of these. And we're looking to do this international collaboration with colleagues in the EU as well. So that is something that we just launched a task force  to develop a listing of core critical data elements to collect on patients and then developing the registries for a number of these rare cancers. Emily Zabor: That sounds like it's going to be a really valuable resource for planning and designing future clinical trials, so I'm glad to hear about that. Dr. Gregory Reaman: And we would invite anyone who's interested to find out about the CCDI, to find out more about the CCDI, which they can do through cancer.gov/ccdi. There is an opportunity for people to register for newsletters. We have a series of webinars, many of which are designed now to actually provide training on some of the resources and platforms that are available currently through the ecosystem and things that we have all planned for future developments and use. So as I said, this is a community venture and we look to expand the community in every way possible. Emily Zabor: That sounds great. So hopefully our listeners will take note of some of those resources in addition to this paper being out there, which will guide some people in the right direction to learn about this really great initiative for childhood cancer.  So, Dr. Reaman, it has been a pleasure speaking with you. And thank you so much for joining me today on this episode of JCO Article Insights. Dr. Gregory Reaman: Thank you very much. It's been great to be here. Appreciate the opportunity.  Emily Zabor: This concludes this episode on the article, “The Childhood Cancer Data Initiative Using the Power of Data to Learn from and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer.” Thank you all for listening and please tune in for the next issue of JCO Article Insights.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Bridgeport Superintendent Carmela Levy-David has officially started in her new role this week. Learn her career story and her plans for the city's student body. ((00:00)) Oh-Oh-NO, Ozempic! A new lawsuit was filed against the makers of Ozempic and Mounjaro for claims of causing stomach paralysis in users. We spoke with Dr. Andrew Wong, Fairfield Region Medical Director of Hartford HealthCare Primary Care. He came back on to discuss the health concerns with this drug if people are solely using it as a weight loss solution. ((14:18)) There are new colon cancer screening guidelines and it's causing MAJOR confusion! Dr. Charles Cha with the Cancer Institute at St. V's explains the new recommendation and how many doctors are responding. ((30:31))

Dr. Patel is a board-certified radiologist. He has a fellowship in Body Imaging, is MQSA Certified, and is the Director of Breast Imaging. For more information about Hamilton Health Care System's imaging services, visit HamiltonHealth.com/imaging. To make an appointment for imaging at Hamilton Diagnostics Center or a mammogram at People's Cancer Institute, call 706-272-6565. To learn more about Peeples Cancer Institute, visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Join A Cure in Sight in an interview with Dr. David Ancona, the founder of Mexico's pioneer Eye Cancer Institute. In this episode, Dr. Ancona and podcast host, Danet Peterson discuss the history of the Eye Cancer Institute in Mexico, the treatments they have available, and the effort it has taken to establish an eye cancer institute in Mexico. Their locations are in Monterry, Mexico, as well as Guatelajara, Mexico. They treat patients from all across Mexico, Central America, Southern America, and in some cases near the souther USA border. Their focus is to bring accessible, patient driven care to patients navigating eye cancer of any kind. You can find them on social media to connect and learn more at www.eyecancerinstitute.org. ANNOUNCEMENTS:   5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! May 20, Raleigh, NC https://bit.ly/3KnyTwp   May 21, Washington DC https://bit.ly/3ZotGIZ   June 10, Minneapolis, MN coming soon!   June 11, Philly, PA https://bit.ly/3U4hsUH   July 8, Seattle, WA https://bit.ly/3TTgvP3   July 15, Palo Alto, CA https://bit.ly/3lRFi9D   August 6, NYC/Brooklyn/Jersey area https://bit.ly/40KUtQH   Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org   Swing for Sight April 22, 2023 REGISTER for SWING FOR SIGHT TODAY: Subscribe to the newsletter to stay in the know Newsletter link   Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org  The Eye Believe Podcast is brought to you by Castle Biosciences. Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.  This podcast was hosted by Danet Peterson and produced by Page Fronczek.

Join Emily Landry and Gloria Moncrief Holmsten (Moncrief Cancer Foundation) in a new episode of our WPCares podcast series as they discuss the importance of cancer prevention and screenings, early detection, and the resources available to the community through Moncrief Cancer Institute. Emily Landry is Whitley Penn's Nonprofit Industry Leader for Tax and Client Accounting & Advisory Services, and works closely with Moncrief Cancer Institute. As part of her work, Emily learns about the incredible impact nonprofit organizations are having on our communities. Through our WPCares series, Emily and others bring awareness to some of these amazing nonprofits and their resources.

https://www.GoodMorningGwinnett.com Listen to the show Monday-Thursday at 10am. Learn all about people and places around Gwinnett County. Hey if you're enjoying the show, horoscope & morning inspiration, help me keep up the good feelings by buying me a cup of coffee. Just click the link below. https://www.buymeacoffee.com/AudreyBK_________________________________________Northside Hospital is committed to expanding access to leading health care across Georgia. The health system announces the following network updates. Radiotherapy Clinics of Georgia, a partner in The US Oncology Network, in Lawrenceville is now part of Northside Hospital Cancer Institute. Northside Hospital Radiation Oncology – Duluth Highway – Lawrenceville is located at 698 Duluth Highway, Suite 100, Lawrenceville, GA 30046. Northside Hospital Radiation Oncology – Philip Blvd – Lawrenceville is located at 311 Philip Blvd., Lawrenceville, GA 30046. Both facilities opened for patients on Monday, April 3. Patients have access to the same compassionate care and nationally recognized physicians they have come to know. Both locations will offer the same providers and services. With the new partnership, patients also have access to Georgia's largest cancer network and the latest cancer research and treatments available.

This episode features Dr. Joseph Uberti, Medical Oncologist and Interim President & CEO of the Karmanos Cancer Institute, joins the podcast to talk about his background, the biggest issues he's following in healthcare going forward in 2023, what the most effective healthcare leaders need to be successful in the next 2-3 years, and more.

Evan Walgama, MD is a board-certified Otolaryngologist – Head & Neck / ENT Surgeon at the Pacific Eye, Ear & Skull Base Center at Pacific Neuroscience Institute, Santa Monica. His particular area of expertise is in the treatment of patients with benign and malignant tumors of the head and neck.Dr. Walgama is a dual-fellowship trained surgeon. He completed his Sinus and Skull Base fellowship at Stanford, followed by a Head and Neck Surgical Oncology fellowship at MD Anderson. He brings together both skillsets to treat challenging cancers of the ear, nose and throat, with a priority focus on preservation of quality of life for patients and their families. As a leader of a multidisciplinary team, Dr. Walgama addresses a wide array of benign and malignant tumors of the head and neck, including thyroid, oral cavity, throat, HPV-related, and sinus/skull base. He is a champion of multidisciplinary care and patient-centered decision making, seeing patients at award-winning Providence hospitals – Saint John's Health Center, Santa Monica, and Little Company of Mary Medical Center, Torrance, California. At Saint John's Cancer Institute, Dr. Walgama's research and academic interests include cost-effectiveness, clinical outcomes research, and clinical trials in head and neck oncology. Dr. Walgama is a member of the American Head & Neck Society, the North American Skull Base Society, and the American Academy Otolaryngology. To learn more about Dr. Walgama please visit https://www.pacificneuroscienceinstitute.org/people/evan-walgama/

Brain tumors don't get the same amount of attention as the other types of cancers. But they are still very important to talk about. My guest today is Dr. Daniel F. Kelly, a neurosurgeon and founder of Pacific Neuroscience Institute. Listen in to learn about Daniel's non-linear path to becoming a neurosurgeon. You'll also hear how the Pacific Neuroscience Institute uses keyhole surgery to reduce the amount of time patients need to stay in the hospital.   What You'll Learn: We learn about Dr. Daniel F. Kelly and his background. (2:00) Daniel explains his non-linear path to becoming a neurosurgeon. (3:40) I recount some of my experiences with neurosurgeons.  (5:30) Seeing a gap in specialized neuro-oncology at St. John's Cancer Institute, Daniel helped found the Pacific Neuroscience Institute.  (6:00) Daniel describes the types of tumors he sees most and how that's changed over time. (8:15) We hear how Daniel got interested in pituitary tumors. (10:20) Pacific Neuroscience Institute uses a lot of collaboration to give the patient the best care (13:05) We hear how patients' pathways may differ when treated by Daniel. (14:26) Not every brain tumor patient requires surgery. (17:20) The essence of keyhole surgery is to sneak in and sneak out. (18:36) Daniel explains how surgery has evolved throughout his career. (21:30) Not every neurosurgeon specializes in keyhole surgery. (22:00) The COVID-19 pandemic reduced the amount of time neuro-patients stayed in hospitals post surgery. (24:30) Neuro-patients are incredibly brave and resilient. (27:16) Daniel explains how he collaborates with different specialists. (30:00) There are some exciting advances happening in neurosurgery. (32:00) Pacific Neuroscience Institute is looking for a cure for Glioblastoma. (35:05) Psychedelic assisted therapy is currently having a renaissance. (36:30) Daniel describes various studies on psychedelic assisted therapy. (39:14) We discuss the Netflix show 'How to Change Your Mind'. (44:00)   Ideas worth sharing: "Not everyone who has a brain tumor needs surgery." - Dr. Daniel F. Kelly   "The essence of Keyhole Surgery is to sneak in and sneak out with minimum collateral damage." - Dr. Daniel F. Kelly   "Managing patient expectations is important for all areas of oncology." - Dr. Rosalyn Morrell   "All of my patients teach me so much. We think we're teaching them and educating them -- but a lot of times it's the other way around." - Dr. Rosalyn Morrell   Resources: Dr. June Wiley: USC Pacific Neuroscience Institute: Website Dr. Daniel F. Kelly: Email

On the latest episode of Territory Talk, co-hosts Doug Plagens and Jameson Olive discuss the latest road trip and upcoming homestand for the Florida Panthers. Plus, Dr. Michael Zinner, who serves as the Chief Executive Officer and Executive Medical Director of Baptist Health's Miami Cancer Institute, joins the show to talk about Saturday's “Hockey Fights Cancer Night” and more.Highlights of the episode include:Looking back at Florida's four-game road trip. (1:45)Brandon Montour steps into the spotlight. (6:30)Dr. Zinner of Baptist Health Miami's Cancer Institute joins the show! (19:15)Doug and Jameson are off to a rough start in the prediction game. (29:00)

Yes, Howard Brown is a two-time cancer survivor. As you will discover in our episode, he grew up with an attitude to thrive and move forward. Throughout his life, he has learned about sales and the concepts of being a successful entrepreneur while twice battling severe cancer.   Howard's life story is one of those events worth telling and I hope you find it worth listening to. He even has written a book about all he has done. The book entitles Shining Brightly has just been released, but you get to hear the story directly from Howards' lips.   About the Guest: Howard Brown is an author, speaker, podcaster, Silicon Valley entrepreneur, interfaith peacemaker, two-time stage IV cancer survivor, and healthcare advocate. For more than three decades, Howard's business innovations, leadership principles, mentoring and his resilience in beating cancer against long odds have made him a sought-after speaker and consultant for businesses, nonprofits, congregations, and community groups. In his business career, Howard was a pioneer in helping to launch a series of technology startups before he co-founded two social networks that were the first to connect religious communities around the world. He served his alma mater—Babson College, ranked by US News as the nation's top college for entrepreneurship—as a trustee and president of Babson's worldwide alumni network. His hard-earned wisdom about resilience after beating cancer twice has led him to become a nationally known patient advocate and “cancer whisperer” to many families. Visit Howard at ShiningBrightly.com to learn more about his ongoing work and contact him. Through that website, you also will find resources to help you shine brightly in your own corner of the world. Howard, his wife Lisa, and his daughter Emily currently reside in Michigan. About the Host: Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog.   Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards.   https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/   accessiBe Links https://accessibe.com/ https://www.youtube.com/c/accessiBe https://www.linkedin.com/company/accessibe/mycompany/ https://www.facebook.com/accessibe/       Thanks for listening! Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below!   Subscribe to the podcast If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can also subscribe in your favorite podcast app.   Leave us an Apple Podcasts review Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts.     Transcription Notes Michael Hingson  00:00 Access Cast and accessiBe Initiative presents Unstoppable Mindset. The podcast where inclusion, diversity and the unexpected meet. Hi, I'm Michael Hingson, Chief Vision Officer for accessiBe and the author of the number one New York Times bestselling book, Thunder dog, the story of a blind man, his guide dog and the triumph of trust. Thanks for joining me on my podcast as we explore our own blinding fears of inclusion unacceptance and our resistance to change. We will discover the idea that no matter the situation, or the people we encounter, our own fears, and prejudices often are our strongest barriers to moving forward. The unstoppable mindset podcast is sponsored by accessiBe, that's a c c e s s i  capital B e. Visit www.accessibe.com to learn how you can make your website accessible for persons with disabilities. And to help make the internet fully inclusive by the year 2025. Glad you dropped by we're happy to meet you and to have you here with us.   Michael Hingson  01:20 Hi, and welcome to another episode of unstoppable mindset. Today, we get to interview Howard Brown, I'm not going to tell you a lot because I want him to tell his story. He's got a wonderful story to tell an inspiring story. And he's got lots of experiences that I think will be relevant for all of us and that we all get to listen to. So with that, Howard, welcome to unstoppable mindset.   Howard Brown  01:44 Thank you, Michael. I'm really pleased to be here. And thanks for having me on your show. And excited to talk to your audience and and share a little bit.   Michael Hingson  01:54 Well, I will say that Howard and I met through Podapolooza, which I've told you about in the past and event that brings podcasters would be podcasters. And people who want to be interviewed by podcasters together, and Howard will tell us which were several of those he is because he really is involved in a lot of ways. But why don't you start maybe by telling us a little bit about your, your kind of earlier life and introduce people to you and who you are. Sure, sure.   Howard Brown  02:23 So I'm from Boston. I can disguise the accent very well. But when I talked to my mother, we're back in Boston, we're packing a car. We're going for hot dogs and beans over to Fenway Park. So gotta get a soda. We're getting a soda, not a pop. So we add the Rs. They call my wife Lisa, not Lisa. But I grew up I grew up in the suburbs of Boston, a town called Framingham. And I'm a twin. And I'm very unusual. But a girl boy twin, my twin sister Cheryl. She goes by CJ is five minutes older. And I hold that I hold that now against her now that we're older and she didn't want to be older, but now she's my older sister, my big sister by five whole minutes.   Michael Hingson  03:09 Well, she's big sister, so she needs to take care of her baby brother   Howard Brown  03:12 says exactly. And she did. And we're gonna get to that because it's a really important point being a twin, which we'll get to in a second. But so Britta she Where does she live now? So she lives 40 minutes away from me here in Michigan.   Michael Hingson  03:25 Oh my gosh, you both have moved out of the area.   Howard Brown  03:27 So she she moved to Albany, New York. I moved to Southern then California, LA area and the beaches, and then Silicon Valley. And then the last 17 years we've all lived close. And we raised our families together here in the suburbs of Detroit, Michigan.   Michael Hingson  03:40 What got you to all go to Michigan?   Howard Brown  03:43 Well, for me, it was a choice. My wife is from Michigan, and I was in Silicon Valley. And we were Pat had a little girl Emily, who's four. There's a story there too. But we'll we decided we wanted her to grow up with a family and cousins and aunts and uncles and my in laws live here. My wife grew up here. And this made it closer for my parents and Boston suburbs to get here as well. So great place to raise a family very different from Silicon Valley in Palo Alto, California.   Michael Hingson  04:12 Yeah, but don't you miss Steve's ice cream in Boston?   Howard Brown  04:15 I do. I miss the ice cream. I missed the cannolis in the Back Bay. I missed some of the Chinese food. So in the north end, but it just it I do, but I have not lived there. I went to college there at Babson College number one school for entrepreneurship. And then when I got my first job, I moved out to Ohio but then I moved back and well there's a whole story of why I had to move back as well but we'll get   Michael Hingson  04:41 there. So are your parents still living in Boston?   Howard Brown  04:46 They are and so my dad I call myself son of a boot man. My dad for 49 years has sold cowboy boots in New England in the in the in the western you know the states New York Maine, New Hampshire, Vermont, Connecticut, Rhode Island, Massachusetts. And that's, you know, anyone who stayed somewhere for 49 years got to be applauded. And he's a straight commission boot salesman and he sold women's shoes prior to that. So he he's, he's a renaissance man.   Michael Hingson  05:15 Wow. So does he sell cowboy boots with snow treads as it were for the winter?   Howard Brown  05:21 No snow trends but, you know, like out west when you're working on, you know, on with cattle and working out west and sometimes it's a fashion statement. Not not too many places in New England like that. But he, he made a living, he enjoyed it. And he's, he's just about to retire at the age of 79. This year.   Michael Hingson  05:39 I remember living in Boston and and when I wear shoes with just leather soles, I slid around a lot on the sidewalks and all that so did get rubber rubbers to go over my boots and then later got real boots.   Howard Brown  05:54 Right. So I have the big hiking boots, the Timberlands, but I too have a pair of a you know, in Boston, we call them rabbits, rabbits, robins. And they basically are slip ons that gave you grip. They slipped right over your leather shoes. And you wore them when anyway in the snow and in those sloshing in the mess. Yeah.   Michael Hingson  06:12 And they worked really well. They did. So you went off to college. And I gather kind of almost right from the beginning you got involved in the whole idea of entrepreneurship.   Howard Brown  06:23 Well, I did I transferred to Babson from a liberal arts school called Connecticut College. I just I found out it wasn't for me and Babson College changed the trajectory of my entire life. i i I knew that I wanted to do sales and then later technology. But Babson was the catalyst for that. They just they support entrepreneurship of all kinds, no matter how you define it, and I just drank it in and I loved, I loved my time there. I love my learning there. And I continue to stay involved with Babson very closely as a past president of the Alumni Association, a former trustee, and very actively recruit students to go there and support student businesses. So it was a big impact on me and I continue to give back to it.   Michael Hingson  07:11 That's pretty cool. So how, how did you proceed as far as a career and entrepreneurial involvement as it were in in sales and all that?   Howard Brown  07:22 So I had an internship, I had wanted cellular one when cellular phones came out and I was basically learning the business. This is really early 1984 And five, and then I got another internship at NCR Corporation if you remember national cash register 120 year old company based out of Dayton, Ohio, and now it's in Atlanta, and it's, it's just not the same company. But I took an internship there a lot of Babson folks work there. And I worked as a trainer, sales installation rep. I trained waitresses, waiters, bartenders, hotel clerks, night audits, how to use cash register computer systems. So I was the teacher and a trainer. And I would, you know, talk to waitresses and waiters and bartenders and say you can make more tips by providing better service. But the way that you do that is you type you the order into a computer, it zaps it to the order station or the back to the back of the house to cook to prepare the foods or for the drinks. And you can spend more time servicing your table which should translate into higher tips. Well, about a third of them said nope, not for me, a third of them were need to be convinced and a third of them are like I'm in. I had a lot of fun doing that. And then after the shift, the either the manager or the owner would come over and they'd give you a savior at a Chinese food restaurant. They give you a poopoo platter to go to take home to your dorm room.   Michael Hingson  08:46 So I had a lot of fun, a lot of fun and a lot of good food.   Howard Brown  08:50 Sure sure. So that's what really started me off and hired me   Michael Hingson  08:55 so did that did that concept of tips and all that and advising people ever get you to translate that to Durgin Park?   Howard Brown  09:03 I actually did install the cashiers to computers area ago Daniel hall so the checkerboard you know draped you know cloth on the table and so you know it's there's a lot of good restaurants in Boston, you know the union Oyster House with a toothpick but I did countless restaurants hotels bars, you know it was I was basically at the whim of the Salesforce and there was a couple of us that went to go train and teach people and take the night shift and make sure everything was going smoothly as they installed the new system of course the no name restaurant and other one but well you know for for your listeners that no name was a place to get, you know, really great discounted seafood but you sat on a park bench. Remember that?   Michael Hingson  09:50 Right? Oh yeah, definitely. It wasn't. Well, neither was Durgin park, but I haven't kept up Is it still there?   Howard Brown  10:00 Yes, I believe it's still there.   Michael Hingson  10:01 Oh, good. I heard somewhere that, that it might not be because of COVID. But we enjoy   Howard Brown  10:07 down it shut down for a while during COVID I hope it's back open. I'm gonna have to go now. Yeah, you're gonna make me go check to see if it's open. But you know, many of them are still there. And obviously restaurants turn over. But that's a mainstay that's got a lot of history.   Michael Hingson  10:19 Oh, it does. And we had a lot of fun with the waitresses and so on at their Compac. I know, once we went there, and you know, the whole story, that Durgan is a place where you sit at family tables, unless we actually have four people then they'll let you sit at one of the tables for for around the outside. Well, there were three of us and my guide dog when we went in one time. And the hostess said, we're gonna put you at one of the tables for for just to give more room for the puppy dog. And she sat us down there. Then the waitress came over and as they are supposed to do at Durgan Park, she said, you're not supposed to sit here. There are only three of you. And I said there's a dog under the table. No, there's not. You can't fool me with that. And the waitress isn't supposed to be snotty, right. And she just kept going on and on about it. And I kept saying there is a dog under the table. She went away. And then she came back a little bit later. And she said, You've got to move and I said no. Why don't you just look, there's a dog under the table. You're not gonna make me fall for that. She finally looked. And there are these Golden Retriever puppy eyes staring back at her. She just melted. It was so much fun.   Howard Brown  11:26 Wouldn't be Boston if you didn't get a little attitude. Well, yeah, that's part of what it's all about your right next seating. And they just they sit you in a and they say, meet each other and be married.   Michael Hingson  11:38 Yeah, yeah. And it was a lot of fun. So how long did it take you to get to Silicon Valley?   Howard Brown  11:44 Well, so the story is that I did. I worked for NCR and I got hired by NCR, but I wanted out of the hospitality business. You know, even though he's young work until two, three in the morning, once they shut the restaurant or bar down or the hotel down, and then you do the night audit and you do the records. It was a hard life. So I looked and I did my research. And I said, you know who's who's making all the money here at NCR in the banking division. And it was really the early days of the outsourcing movement, punch cards, and you're outsourcing bank accounts, over 1200 baud modems. And I said, Well, that's interesting. And so I went to NCRs training at Sugar camp to learn how to be a salesperson were they actually in the early days, they filmed you, they taught you negotiation skills, competitive analysis, Industry Skills, it was fantastic. It's like getting an MBA today. But they did it all in six months, with mixing fieldwork in with, you know, training at this education facility in Dayton, Ohio. And I came out as a junior salesperson working for for very expansive experience, guys. And they just, I knew one thing, if I made them more productive, they'd make me money. And I did. And I, they sent me to banks and savings and loans and credit unions all over New England. And I basically learned the business of banking and outsourcing to these banks. And they made a lot of money. So that was how my career started. You can't do better than that. But to answer the question, because it's a little more complex than that. But it took me NCR in 1988. And then I moved out to Los Angeles in 1991, after a big health scare, which we'll talk about, and then I moved up in 2005. So there's the timeline to get me to Silicon Valley.   Michael Hingson  13:29 So you, you definitely moved around. I know that feeling well, having had a number of jobs and been required to live in various parts of the country when going back and forth from one coast to another from time to time. So you know, it's it's there. So you, you did all of that. And you You ended up obviously making some money and continuing to to be in the entrepreneurial world. But how does that translate into kind of more of an entrepreneurial spirit today?   Howard Brown  14:00 So great question, Michael. So what happened was is that I built a foundation. So at that time when you graduated school, and as far as for technology, the big computer shops like IBM Unisys, NCR, Hewlett Packard, what they did is they took you raw out of college, and they put you through their training program. And that training program was their version of the gospel of their of their products and your competitors and all that. And that built a great foundation. Well, I moved to Los Angeles after this big health scare, which I'm sure we're gonna go back and talk about, and I moved into the network products division. So I didn't stay in the banking division. I looked at the future and said voice data and video. I think there's the future there and I was right and AT and T bought NCR and, unfortunately, this is probably 1992. They also bought McCaw cellular they had just bought all of Eddie computer. They were a big company of five 600,000 employees and I have To tell you, the merger wasn't great. You felt like a number. And I knew that was my time. That was my time where I said, I got my foundation built. It's now time to go to a startup. So your time had come. My time had come. So at&t, offered early retirement for anyone 50 and older, and then they didn't get enough takers. So they offered early retirement for anyone that wanted to change. And so the talk around the watercooler was, let's wait they'll make a better offer. And I was like, I'm 26 and a half years old. I what am I waiting for? So they made a tremendously generous offer. I took early retirement, and I moved to my first true startup called avid technology that was in the production space. And we basically were changing film and television production from analog to digital. And I never looked back, I basically have been with startups ever since. And that, but that foundation I felt was really important that I got from NCR, but I prefer smaller companies and build the building them up from scratch and moving them forward.   Michael Hingson  16:07 Yeah, when you can do more to help shape the way they go. Because the the problem with a larger a lot of larger companies is they get very set in their ways. And they tend not to listen as much as maybe they should to people who might come along with ideas that might be beneficial to them, as opposed to startups as you say,   Howard Brown  16:27 Well, it depends. I mean, you know, you want to build a company that is still somewhat innovative. So what these large companies like Google and Facebook do, and Apple is they go acquire, they acquire the startups before they get too big or sometimes like, it's like what Facebook did with Instagram, they acquired six people, Google acquired YouTube, and they acquire the technology of best of breed technology. And then they shape it, and they accelerate it up. So listen, companies like IBM are still innovative, Apple, you know, is so innovative. But you need to maintain that because it can get to be a bureaucracy, and with hundreds of 1000s of employees. And you can't please everybody, but I knew my calling was was technology startups. And I just, I needed to get that, get that foundation built. And then away away I went. And that's what I've done. Since   Michael Hingson  17:16 you're right. It's all about with with companies, if they want to continue to be successful, they have to be innovative, and they have to be able to grow. I remember being in college, when Hewlett Packard came out with the HP 25, which was a very sophisticated calculator. Back in the the late 19th, early 1970s. And then Texas Instruments was working on a calculator, they came out with one that kind of did a lot of the stuff that HP did. But about that same time because HP was doing what they were doing, they came out with the HP 35. And basically it added, among other things, a function key that basically doubled the number of incredible things that you could do on the HP 25.   Howard Brown  17:58 Right, I had a TI calculator and in high school.   Michael Hingson  18:02 Well, and of course yeah, go ahead HPUS pull reverse Polish notation, which was also kind   Howard Brown  18:09 of fun. Right and then with the kids don't understand today is that, you know, we took typing, I get I think we took typing.   Michael Hingson  18:19 Did you type did you learn to type on a typewriter without letters on the keys?   Howard Brown  18:23 No, I think we have letters I think you just couldn't look down or else you get smacked. You know, the big brown fox jumped over the you know, something that's I don't know, but I did learn but I I'm sort of a hybrid. I looked down once in a while when I'd say   Michael Hingson  18:39 I remember taking a typing course in actually it was in summer school. I think it was between seventh and eighth grade. And of course the typewriters were typewriters, typewriters for teaching so they didn't have letters on the keys, which didn't matter to me a whole lot. But by the same token, that's the way they were but I learned to type and yeah, we learned to type and we learned how to be pretty accurate with it's sort of like learning to play the piano and eventually learning to do it without looking at the keys so that you could play and either read music or learn to play by ear.   Howard Brown  19:15 That's true. And And again, in my dorm room, I had Smith Corona, and I ended up having a bottle of or many bottles of white out.   Michael Hingson  19:25 White out and then there was also the what was it the other paper that you could put on the samosa did the same thing but white out really worked?   Howard Brown  19:33 Yeah, you put that little strip of tape and then it would wait it out for you then you can type over it. Right? We've come a long way. It's some of its good and some of its bad.   Michael Hingson  19:43 Yeah, now we have spellchecker Yeah, we do for what it's worth,   Howard Brown  19:49 which we got more and more and more than that on these I mean listen to this has allowed us to, to to do a zoom call here and record and goods and Bad's to all of that.   Michael Hingson  19:58 Yeah, I still I have to tell people learning to edit. Now using a sound editor called Reaper, I can do a lot more clean editing than I was able to do when I worked at a campus radio station, and had to edit by cutting tape and splicing with splicing tape.   Howard Brown  20:14 Exactly. And that's Yeah, yeah, Michael, we change the you know, avid changed the game, because we went from splicing tape or film and Betamax cassettes in the broadcast studios to a hard drive in a mouse, right? changed, we changed the game there because you were now editing on a hard drive. And so I was part of that in 1994. And again, timing has to work out and we had to retrain the unions at the television networks. And it was, for me, it was just timing worked really well. Because my next startup, liquid audio, the timing didn't work out well, because we're, we were going to try to do the same thing in the audio world, which is download music. But when you do that, when you it's a Sony cassette and Sony Walkman days, the world wasn't ready yet. We we still went public, we still did a secondary offering. But we never really brought product to market because it took Steve Jobs 10 years later to actually sell a song for 99 cents and convince the record industry that that was, you know, you could sell slices of pizza instead of the whole pizza, the whole record out   Michael Hingson  21:17 and still make money. I remember avid devices and hearing about them and being in television stations. And of course, for me, none of that was accessible. So it was fun to to be able to pick on the fact that no matter what, as Fred Allen, although he didn't say it quite this way, once said they call television the new medium, because that's as good as it's ever gonna get. But anyway, you know, it has come a long way. But it was so sophisticated to go into some of the studios with some of the even early equipment, like Avid, and see all the things that they were doing with it. It just made life so much better.   Howard Brown  21:52 Yeah, well, I mean, you're not I was selling, you know, $100,000 worth of software on a Macintosh, which first of all the chief engineers didn't even like, but at the post production facilities, they they they drank that stuff up, because you could make a television commercial, you could do retakes, you could add all the special effects, and it could save time. And then you could get more revenue from that. And so it was pretty easy sale, because we tell them how fast they could pay off to the hardware, the software and then train everybody up. And they were making more and more and better commercials for the car dealerships and the local Burger Joint. And they were thrilled that these local television stations, I can tell you that   Michael Hingson  22:29 I sold some of the first PC based CAD systems and the same sort of thing, architects were totally skeptical about it until they actually sat down and we got them in front of a machine and showed them how to use it. Let them design something that they could do with three or four hours, as opposed to spending days with paper and paper and paper and more paper in a drafting table. And they could go on to the next project and still charge as much.   Howard Brown  22:53 It was funny. I take a chief engineer on to lunch, and I tried to gauge their interest and a third, we're just enthusiastic because they wanted to make sure that they were the the way that technology came into the station. They were they were the brainchild they were the they were the domain experts. So a third again, just like training waitresses and waiters and bartenders, a third of them. Oh, they wanted they just wanted to consume it all. A third of them were skeptical and needed convincing. And a third of whom was like, that's never going out on my hair anywhere. Yeah, they were the later and later adopters, of course.   Michael Hingson  23:24 And some of them were successful. And some of them were not.   Howard Brown  23:28 Absolutely. We continue. We no longer. Go ahead. No, no, of course I am the my first sales are the ones that were early adopters. And and then I basically walked over to guys that are later adopters. I said, Well, I said, you know, the ABC, the NBC and the fox station and the PBS station habit, you know, you don't have it, and they're gonna take all your post production business away from you. And that got them highly motivated.   Michael Hingson  23:54 Yeah. And along the way, from a personal standpoint, somebody got really clever. And it started, of course at WGBH in Boston, where they recognize the fact that people who happen to be blind would want to know what's going on on TV when the dialog wasn't saying much to to offer clues. And so they started putting an audio description and editing and all that and somebody created the secondary audio programming in the other things that go into it. And now that's becoming a lot more commonplace, although it's still got a long way to go.   Howard Brown  24:24 Well, I agree. So but you're right. So having that audio or having it for visually impaired or hearing impaired are all that they are now we're making some progress. So it's still a ways to go. I agree with you.   Michael Hingson  24:36 still a ways to go. Well, you along the way in terms of continuing to work with Abbott and other companies in doing the entrepreneurial stuff. You've had a couple of curveballs from life.   Howard Brown  24:47 I have. So going back to my promotion, I was going driving out to Dayton, Ohio, I noticed a little spot on my cheekbone. didn't think anything of it. I was so excited to get promoted and start my new job. up, I just kept powering through. So a few weeks after I'd moved out to Dayton, Ohio, my mom comes out. And she's at the airport and typical Boston and mom, she's like, What's that on your cheek? What's that on your cheek? And I was like, Mom, it's nothing. I kind of started making excuses. I got hit playing basketball, I got it at the gym or something. And she's like, well, we got to get that checked out. I said, No, Mom, it's okay. It's not no big deal. It's a little little market. Maybe it's a cyst or pebble or something I don't know. So she basically said she was worried, but she never told me. So she helped set up my condo, or an apartment. And then she left. And then as long Behold, I actually had to go speak in Boston at the American Bankers Association about disaster recovery, and having a disaster recovery plan. And so this is the maybe August of 1989. And I came back and that spot was still there. And so my mom told my dad, remember, there was payphones? There was no cell phones, no computers, no internet. So she told my dad, she didn't take a picture of it. But now he saw it. And he goes, Let's go play tennis. There's I got there on a Friday. So on a Saturday morning, we'd go do something. And instead of going to play tennis, he took me to a local community hospital. And they took a look at it. And they said off its assist, take some my antibiotic erythromycin or something, you'll be fine. Well, I came back to see them on Monday after my speech. And I said, I'm not feeling that great. Maybe it's the rethrow myosin. And so having to be four o'clock in the afternoon, he took me to the same emergency room. And he's and I haven't had the same doctor on call. He actually said, You know what, let's take a biopsy of it. So he took a biopsy of it. And then he went back to the weight room, he said, I didn't get a big enough slice. Let me take another. So he took another and then my dad drove me to the airport, and I basically left. And my parents called me maybe three weeks later, and they said, You got to come back to Boston. We gotta go see, you know, they got the results. But you know, they didn't tell us they'll only tell you. Because, you know, it's my private data. So I flew back to Boston, with my parents. And this time, I had, like, you know, another doctor there with this emergency room doctor, and he basically checks me out, checks me out, but he doesn't say too much. But he does say that we have an appointment for you at Dana Farber Cancer Institute at 2pm. I think you should go. And I was like, whoa, what are you talking about? Why am I going to Dana Farber Cancer Institute. So it gets, you know, kind of scary there because I show up there. I'm in a suit and tie. My dad's in a suit down. My mom's seems to be dressed up. And we go, and they put me through tests. And I walk in there. And I don't know if you remember this, Michael. But the Boston Red Sox charity is called the Jimmy fund. Right? And the Jimmy fund are for kids with blood cancers, lymphoma leukemias, so I go there. And they checked me in and they told me as a whole host of tests they're going to do, and I'm looking in the waiting room, and I see mostly older people, and I'm 23 years old. So I go down the hallways, and I see little kids. So I go I go hang out with the little kids while I'm waiting. I didn't know what was going on. So they call me and I do my test. And this Dr. George Canalis, who's you know, when I came to learn that the inventor of some chemo therapies for lymphomas very experienced, and this young Harvard fellow named Eric Rubin I get pulled into this office with this big mahogany desk. And they say you have stage four E T cell non Hodgkins lymphoma. It's a very aggressive, aggressive, very aggressive form of cancer. We're going to try to knock this out. I have to tell you, Michael, I don't really remember hardly anything else that was said, I glossed over. I looked up at this young guy, Eric Rubin, and I said, What's he saying? I looked back out of the corner of my eye, my mom's bawling her eyes out. My dad's looks like a statue. And I have to tell you, I was really just a deer in the headlights. I had no idea that how a healthy 23 year old guy gets, you know, stage four T cell lymphoma with a very horrible prognosis. I mean, I mean, they don't they said, We don't know if we can help you at the world, one of the world's foremost cancer research hospitals in the world. So it was that was that was a tough pill to swallow. And I did some more testing. And then they told me to come back in about a week to start chemotherapy. And so, again, I didn't have the internet to search anything. I had encyclopedias. I had some friends, you know, and I was like, I'm a young guy. And, you know, I was talking to older people that potentially, you know, had leukemia or different cancer, but I didn't know much. And so I I basically showed up for chemotherapy, scared out of my mind, in denial, and Dr. RUBIN comes out and he says, we're not doing chemo today. I said, I didn't sleep awake. What are you talking about? He says, we'll try again tomorrow, your liver Our function test is too high. And my liver function test is too high. So I'm starting to learn but I still don't know what's going on. He says I got it was going to field trip. Field Trip. He said, Yeah, you're going down the street to Newton Wellesley hospital, we're going to the cryogenic center, cryo, what? What are you talking about? He goes, it's a sperm bank, and you're gonna go, you know, leave a sample specimen. And it's like, you just told me that, you know, if you can help me out what why I'm not even thinking about kids, right now. He said, Go do it. He says what else you're going to do today, and then you come back tomorrow, and we'll try chemo. So thank God, he said that, because I deposited before I actually started any chemotherapy, which, you know, as basically, you know, rendered me you know, impotent now because of all the chemotherapy and radiation I had. So that was a blessing that I didn't know about until later, which we'll get to. But a roll the story forward a little more quickly as that I was getting all bad news. I was relapsing, I went through about three or four different cycles of different chemotherapy recipes, nothing was working. I was getting sicker, and they tight. My sister, I am the twin CJ, for bone marrow transplant and she was a 25% chance of being a match. She happened to be 100% match. And I had to then gear up for back in 1990 was a bone marrow transplant where they would remove her bone marrow from her hip bones, they would scrub it and cleanse it, and they would put it in me. And they would hope that my body wouldn't immediately rejected and die and shut down or over time, which is called graft versus host these that it wouldn't kill me or potentially that it would work and it would actually reset my immune system. And it would take over the malignant cells and set my set me back straight, which it ended up doing. And so having a twin was another blessing miracle. You know that, you know, that happened to me. And I did some immunotherapy called interleukin two that was like, like the grandfather of immunotherapy that strengthened my system. And then I moved to Florida to get out of the cold weather and then I moved out to California to rebuild my life. I call that Humpty Dumpty building Humpty Dumpty version one. And that's that's how I got to California in Southern California.   Michael Hingson  32:15 So once again, your big sister savedthe day,   Howard Brown  32:19 as usual.   Michael Hingson  32:21 That's a big so we go,   Howard Brown  32:23 as we call ourselves the Wonder Twins. He's more. She's terrific. And thank God she gave part of herself and saved my life. And I am eternally grateful to her for that,   Michael Hingson  32:34 but but she never had any of the same issues or, or diseases. I gather. She's been   Howard Brown  32:41 very healthy, except for like a knee. A partial knee replacement. She's been very healthy her whole life.   Michael Hingson  32:48 Well, did she have to have a knee replacement because she kept kicking you around or what?   Howard Brown  32:52 No, she's little. She's five feet. 510 So she never kicked me. We are best friends. My wife's best friend. I know. She is just just a saint. She's She's such a giving person and you know, we take that from our parents, but she she gave of herself of what she could do. She said she do it again in a heartbeat. I don't think I'm allowed to give anybody my bone marrow but if I could, would give it to her do anything for her. She's She's amazing. So she gave me the gift, the gift of life.   Michael Hingson  33:21 So you went to Florida, then you moved to California and what did you do when you got out here?   Howard Brown  33:24 So I ended up moving up to northern California. So I met this girl from Michigan in Southern California, Lisa, my wife have now 28 years in July. We married Lisa Yeah, we got married under the Jewish wedding company's wedding canopies called the hotpot and we're looking at the Pacific Ocean, we made people come out that we had that Northridge earthquake in 94. But this is in July, so things are more settled. So we had all friends and family come out. And it was beautiful. We got it on a pool deck overlooking the Pacific. It was gorgeous. It was a beautiful Hollywood type wedding. And it was amazing. So we got married in July of 94. And then moved up to Silicon Valley in 97. And then I was working at the startups. My life was really out of balance because I'm working 20 hours, you know, a day and I'm traveling like crazy. And my wife says, You know what, you got to be home for dinner if we're going to think about having a family. And we're a little bit older now. 35 and 40. And so we've got to think about these things. And so I called back to Newton Wellesley hospital, and I got the specimen of sperm shipped out to San Jose, and we went through an in vitro fertilization process. And she grew eight eight eggs and they defrosted the swimmers and they took the best ones and put them back in the four best eggs and our miracle baby our frozen kids sickle. Emily was born in August of 2001. Another blessing another miracle. I was able to have a child and healthy baby girl.   Michael Hingson  34:58 So what's Emily doing today?   Howard Brown  35:00 Well, thank you for asking that. So, she is now in Missoula, Montana at a television station called K Pax eight Mountain News. And she's an intern for the summer. And she's living her great life out there hiking, Glacier National Park. And she ran I think she ran down to the Grand Tetons and, and she's learning about the broadcast business and reporting. She's a writer by trade, by trade and in journalism. And she likes philosophy. So she'll be coming back home to finish her senior year, this at the end of the summer at the University of Michigan. And so she's about to graduate in December. And she's, she's doing just great.   Michael Hingson  35:35 So she writes and doesn't do video editing us yet using Abbott or any of the evolutions from it.   Howard Brown  35:41 No, she does. She actually, when you're in a small market station, that's you. You write the script, she does the recording, she has a tripod, sometimes she's she films with the other reporters, but when she they sent her out as an intern, and she just covered the, this, you know, the pro pro life and pro choice rallies, she she records herself, she edits on Pro Tools, which is super powerful now, and a lot less expensive. And then, when she submits, she submits it refer review to the news director and to her superiors. And she's already got, I think, three video stories and about six different by lines on written stories. So she's learning by doing, it's experiential, it's amazing.   Michael Hingson  36:23 So she must have had some experience in dealing with all the fires and stuff out at Yellowstone and all that.   Howard Brown  36:31 So the flooding at Yellowstone, so I drove her out there in May. And I didn't see any fires. But the flooding we got there before that, she took me on a hike on the North Gate of Yellowstone. And she's she's, you know, environmentally wilderness trained first aid trained. And I'm the dad, and I'm in decent shape. But she took me out an hour out and an hour back in and, you know, saw a moose saw a deer didn't see any mountain lion didn't see any Grizzlies, thank God, but we did see moose carcass where the grizzly had got a hold on one of those and, and everybody else to get it. So I got to go out to nature weather and we took a road trip out there this summer, it was a blast. It's the those are the memories, when you've been through a cancer diagnosis that you just you hold on to very dearly and very tight. It was a blast. So that's what he's doing this summer. She'll be back. She'll be back in August, end of August.   Michael Hingson  37:22 That's really exciting to hear that she's working at it and being successful. And hopefully she'll continue to do that. And do good reporting. And I know that this last week, with all the Supreme Court cases, it's it's, I guess, in one sense, a field day for reporters. But it's also a real challenge, because there's so many polarized views on all of that.   Howard Brown  37:44 Well, everybody's a broadcaster now whether it's Facebook, LinkedIn, Instagram, and all the other ones out there, tick tock. So everybody's sort of a reporter now. And you know, what do you believe, and unfortunately, I just can't believe in something in 140 characters or something in two sentences. Yeah, there's no depth there. So sometimes you miss the point, and all this stuff. And then everything's on 24 hours on CNN, on Fox on MSNBC, so it never stops. So I call that a very noisy world. And it's hard to process. You know, all this. It's coming at you so fast in the blink of an eye. So we're in a different time than when we grew up, Michael, it was a slower pace. Today in this digital world. It's, it's, it's a lot and especially COVID. Now, are we just consuming and consuming and binging and all this stuff, I don't think it's that healthy.   Michael Hingson  38:36 It's not only a noisy world, but it's also a world, it's very disconnected, you can say all you want about how people can send tweets back and forth, text messages back and forth and so on. But you're not connecting, you're not really getting deep into anything, you're not really establishing relationships in the way that as you point out, we used to, and we don't connect anymore, even emails don't give you that much connection, realism, as opposed to having meaningful dialogue and meaningful conversations. So we just don't Converse anymore. And now, with all that's going on, in the very divided opinions, there's there's no room for discussion, because everybody has their own opinion. And that's it, there's no room to dialogue on any of it at all, which is really too bad.   Howard Brown  39:21 Yeah, I agree. It's been divisive. And, you know, it's, it's hard because, you know, an email doesn't have the body language, the intent, the emotion, like we're talking right now. And, you know, we're expressing, you know, you know, I'm telling stories of my story personally, but you can tell when I get excited, I smile, I can get animated. Sometimes with an email, you know, you don't know the intent and it can be misread. And a lot of that communication is that way. So, you know, I totally get where you're coming from.   Michael Hingson  39:55 And that's why I like doing the podcasts that we're doing. We get to really have conversation isn't just asking some questions and getting an answer and then going on to the next thing. That's, frankly, no fun. And I think it's important to be able to have the opportunity to really delve into things and have really good conversations about them. I learned a lot, and I keep seeing as I do these podcasts, and for the past 20 plus years, I've traveled around the world speaking, of course, about September 11, and talking about teamwork, and trust, and so on. And as I always say, if I don't learn more than I'm able to teach or impart, then I'm not doing my job very well.   Howard Brown  40:35 So that's exactly and that's, that's where I'm going after the second health concern. You know, I'm now going to teach, I'm gonna inspire, I'm going to educate. And that's, that's, that's what I do, I want to do with the rest of my time is to be able to, you know, listen, I'm not putting my head in the sand, about school shootings, about an insurrection about floods about all that. You gotta live in the real world. But I choose, as I say, I like to live on positive Street as much as possible, but positive street with action. That's, that's what makes the world a better place at the end of the day. So you sharing that story means that one we'll never forget. And you can educate the generations to come that need to understand, you know, that point in time and how it affected you and how you've dealt with it, and how you've been able to get back out of bed every day. And I want to do the same.   Michael Hingson  41:26 Well, there's nothing wrong with being positive. I think that there is a need to be aware. But we can we can continue to be positive, and try to promote positivity, try to promote connectionism and conversations and so on, and promote the fact that it's okay to have different opinions. But the key is to respect the other opinion, and recognize that it isn't just what you say that's the only thing that ever matters. That's the problem that we face so much today.   Howard Brown  41:58 Right? Respect. I think Aretha Franklin saying that great. She   Michael Hingson  42:01 did. She did. She's from Motown here. There you go. See? When you moved out to California, and you ended up in Silicon Valley, and so on, who are you working for them?   Howard Brown  42:14 So I moved up, and I worked for this company called Liquid audio that doesn't exist anymore. And it was just iTunes 10 years too early on, there was real audio, there was Mark Cuban's company was called Audio net and then broadcast.com used for a lot of money. And so the company went public and made a lot of money. But it didn't work. The world wasn't ready for it yet to be able to live in this cassette world. It was not ready. I Napster hadn't been invented, mp3 and four hadn't been invented. So it just the adoption rate of being too early. But it still went public a lot. The investors made a ton of money, but they call that failing, failing forward. So I stayed there for a year, I made some money. And I went to another startup. And that startup was in the web hosting space, it was called Naevus. site, it's now won by Time Warner. But at that time, building data centers and hosting racks of computers was very good business. And so I got to be, you know, participate in an IPO. You know, I built built up revenue. And you know, the outsourcing craze now called cloud computing, it's dominated by the folks that like Amazon, and the folks at IBM, and a few others, but mostly, you know, dominated there, where you're basically having lots of blinking lights in a data center, and just making sure that those computers stay up to serve up the pages of the web, the videos, even television, programming, and now any form of communication. So I was, I was early on in that and again, got to go through an IPO and get compensated properly unduly, and, but also my life was out of balance. And so before we were called out for the sperm and had a baby, I transitioned out when Silicon Valley just the pendulum swung the other way, I ended up starting to work at my own nonprofit, I founded it with a couple of Silicon Valley guys called Planet Jewish, and it was still very technologically driven. It was the world's first Community Calendar. This is before Google Calendar, this is in 2000. And we built it as a nonprofit to serve the Jewish community to get more people to come to Jewish events. And I architected the code, and we ran that nonprofit for 17 years. And before calendaring really became free, and very proud of that. And after that, I started a very similar startup with different code called circle builder, and it was serving faith and religions. It was more like private facebook or private online communities. And we had the Vatican as a client and about 25,000 Ministries, churches, and nonprofits using the system. And this is all sort of when Facebook was coming out to you know, from being just an edu or just for college students. And so I built that up as a quite a big business. But unfortunately, I was in Michigan when I started circle builder. I ended up having to close both of those businesses down. One that the revenue was telling off of the nonprofit and also circuit builder wasn't monetizing as quickly or as we needed as well. But I ended up going into my 50 year old colonoscopy, Michael. And I woke up thinking everything was going to be fine. My wife Lisa's holding my hand. And the gastroenterologist said, No, I found something. And when I find something, it's bad news. Well, it was bad news. Stage three colon cancer. Within about 10 days or two weeks, I had 13 and a half inches of my colon removed, plus margins plus lymph nodes. One of the lymph nodes was positive, install a chemo port and then I waited because my daughter had soccer tournaments to travel to but on first week of August in 2016, I started 12 rounds of Rockem sockem chemotherapy called folfox and five Fu and it was tough stuff. So I was back on the juice again, doing chemotherapy and but this time, I wasn't a deer in the headlights, I was a dad, I was a husband. I had been through the trenches. So this time, I was much more of a marine on a mission. And I had these digital tools to reach out for research and for advocacy and for support. Very different at that time. And so I unfortunately failed my chemotherapy, I failed my neck surgery, another colon resection, I failed a clinical trial. And things got worse I became metastatic stage four that means that colon cancer had spread to my liver, my stomach linings called the omentum and peritoneum and my bladder. And I had that same conversation with a doctor in downtown Detroit, at a Cancer Institute and he said, We don't know if we can help you. And if you Dr. Google, it said I had 4% of chances of living about 12 to 18 months and things were dark I was I was back at it again looking looking at the Grim Reaper. But what I ended up doing is research and I did respond to the second line chemotherapy with a little regression or shrinkage. And for that you get more chemotherapy. And then I started to dig in deep research on peritoneal carcinoma which is cancer of the of the of the stomach lining, and it's very tricky. And there's a group called colon town.org that I joined and very informative. I there then met at that time was probably over 100 other people that had had the peritoneal carcinoma, toma and are living and they went through a radical surgery called cytoreduction high pack, where they basically debulk you like a de boning a fish, and they take out all this cancer, they can see the dead and live cells, and then they pour hot chemo in you. And then hot chemo is supposed to penetrate the scanning the organs, and it's supposed to, in theory kill micro cell organism and cancer, although it's still not proven just yet. But that surgery was about a 12 and a half hour surgery in March of 2018. And they call that the mother of all surgeries. And I came out looking like a ghost. I had lost about 60 pounds, and I had a long recovery. It's that one would put Humpty Dumpty back together. It's been now six years. But I got a lot of support. And I am now what's called no evidence of disease at this time, I'm still under surveillance. I was quarterly I just in June, I had my scans and my exams. And I'm now going to buy annual surveillance, which means CAT scans and blood tests. That's the step in the right direction. And so again, I mean, if I think about it, my twin sister saved my life, I had a frozen sperm become a daughter. And again, I'm alive from a stage four diagnosis. I am grateful. I am lucky, and I am blessed. So that's that a long story that the book will basically tell you, but that's where I am today.   Michael Hingson  48:50 And we'll definitely get to the book. But another question. So you had two startups that ran collectively for quite a period of time, what got you involved or motivated to do things in the in the faith arena?   Howard Brown  49:06 So I have to give credit to my wife, Lisa. So we met at the Jewish Federation of Los Angeles at this young leadership group. And then they have like a college fair of organizations that are Jewish support organizations. And one of them happened to be Jewish Big Brothers, now Jewish Brothers and Big Sisters of Los Angeles. Suppose you'd be a great big brother. I was like, well, it takes up a lot of time. I don't know. She's like, you should check it out. So I did. And I became I fill out the application. I went through the background checks, and I actually got to be a Jewish big brother to this young man II and at age 10. And so I have to tell you, one of the best experiences in my life was to become a mentor. And I today roll the clock forward. 29 years in is now close to 40 years old or 39 years old. He's married with a son who's one noble and two wife, Sarah, and we are family. We stayed together past age 18 Seen, and we've continued on. And I know not a lot of people do that. But it was probably one of the best experiences I've ever done. I've gotten so much out of it. Everyone's like, Oh, you did so much for in? Well, he did so much for me and my daughter, Emily calls him uncle and my wife and I are we are his family, his dad was in prison and then passed away and his mom passed away where his family now. And so one of the best experiences. So that's how I kind of got into the Jewish community. And also being in sales I was I ended up being a good fundraiser. And so these nonprofits that live their lifeblood is fundraising dollars. I didn't mind calling people asking them for donations or sitting down over coffee, asking them for donations. So I learned how to do that out in Southern California in Northern California. And I've continued to do that. So that gave me a real good taste of faith. I'm not hugely religious, but I do believe in the community values of the Jewish community. And you get to meet people beyond boards and you get to raise money for really good causes. And so that sort of gave me another foundation to build off of and I've enjoyed doing that as a community sermon for a long time.   Michael Hingson  51:10 I'll bite Where does Ian live today?   Howard Brown  51:13 Okay, well, Ian was in LA when we got matched. I had to move to San Francisco, but I I petitioned the board to keep our match alive because it was scholarship dollars in state right. And went to UC Santa Cruz, Florida State for his master's and got his last degree at Hastings and the Jewish community supported him with scholarships. And in was in very recently was in San Francisco, Oakland area, and now he's lives in South Portland, Oregon.   Michael Hingson  51:39 Ah, so you haven't gotten back to Michigan yet? Although he's getting into colder weather. So there's a chance?   Howard Brown  51:45 Well, let me tell you, he did live with us in Michigan. So using my connections through the Jewish community, I asked if he could interview with a judge from the Ninth Circuit Court of Appeals a friend of mine, we sat on a on a board of directors for the American Jewish Committee, Detroit. And I said, she's like, well, Howard, I really have to take Michigan kids. I said, You know what? No problem. You decide if he's if he's worthy or not go through your process, but would you take the phone call? So she took the phone call, and I never heard anything. And then Ian called me and he said, I got it. I as a second year loss. Going to be a second year law student. I'm going to be clerking for summer interning and clerking for this judge Leanne white. And again, it just it karma, the payback, it was beautiful. So he lived with us for about four and a half months. And when he came back, and it was beautiful, because Emily was only about four or five years old. And, and he lived with us for that time. And it was beautiful.   Michael Hingson  52:43 But that's really great. That, that you have that relationship that you did the big brother program. And I'm assuming you've been big brother to other people as well.   Howard Brown  52:53 No, no. I have not actually. Because what it did is it trained me to be a dad. So when I had Emily, it was more it was more difficult actually to do that. And so no, Ian has been my one and only match. I mentor a lot of Babson students, and I mentor and get mentored by some cancer patients and, and some big entrepreneurs. Mentorship is a core value of mine. I like to be mentored. And I also like to mentor others. And I think that's, that's what makes the world go round. So when Steve Gates when Bill Gates, his wife, Melinda, just donated 123 million to the overall arching Big Brothers, Big Sisters of America. And that money will filter to all those, I think that that's such a core value. If a young person can have someone that takes interest in them, they can really shape their future and also get a lot out of it. So mentorship is one of my key values. And I hope it's hope it's many of your viewers and yours as well. Michael,   Michael Hingson  53:52 absolutely is I think that we can't do anything if we can't pass on what we've learned and try to help other people grow. I've been a firm believer my entire life of you don't give somebody a fish, you teach them how to fish and however, and wherever that is, it's still the same thing. And we need to teach and impart. And I think that in our own way, every one of us is a teacher and the more we take it seriously, the better it is.   Howard Brown  54:18 Well, I'm now a student not learning podcasting. I learned how to be a book author and I'm learning how to reinvent myself virgin Humpty Dumpty, version two coming out.   Michael Hingson  54:29 So you had been a national cancer survivor advocate and so on. Tell me a little bit about that if you would.   Howard Brown  54:35 So I respect people that want to keep their diagnosis private and their survivorship private. That's not me. I want to be able to help people because if I would have been screened at age 40 or 42, I probably wouldn't have had colon cancer and I was not, but this is a preventable disease and really minorities and indigenous people as they need to get screened more, because that's the highest case of diagnosis for colorectal cancer. But what I think that that's what his needs now it's the second leading killer of cancer right now. And it's an important to get this advocacy out and use your voice. And so I want to use my voice to be able to sound the alarm on getting screening, and also to help people survive. There's I think, 16 million growing to 23 or 4 million by 2030. Cancer survivors out there, cancer diagnosis, it sucks sex all the way around, but it affects more than the patient, it affects your caregiver, it affects your family affects relationships, it affects emotions, physical, and also financial, there is many aspects of survivorship here and more people are learning to live with it and going, but also, quite frankly, I live with in the stage for cancer world, you also live with eminence of death, or desperation to live a little bit longer. You hear people I wish I had one more day. Well, I wish I had time to be able to see my daughter graduate high school, and I did and I cherished it. I'm going to see her graduate college this December and then walk at the Big House here in Michigan, in Ann Arbor in May. And then God willing, I will walk her down the aisle at the appropriate time. And it's good to have those big goals that are important that drive you forward. And so those are the few things that drive me forward.   Michael Hingson  56:28 I know that I can't remember when I had my first colonoscopy. It's been a while. It was just part of what I did. My mother didn't die of colon cancer, but she was diagnosed with colon cancer. She, she went to the doctor's office when she felt something was wrong. And they did diagnose it as colon cancer. She came home my brother was with her. She fell and broke her hip and went into the hospital and passed away a few days later, they did do an operation to deal with repairing her hip. And but I think because of all of that, just the amount that her body went through, she just wasn't able to deal with it. She was 6970. And so it was no I take Yeah, so I was just one of those things that that did happen. She was 71, not 70. But, you know, we've, for a while I got a colonoscopy every five years. And then they say no, you don't need to do it every five years do it every 10 years. The couple of times they found little polyps but they were just little things. There was nothing serious about them. They obviously took them out and autopsy or biopsy them and all that. And no problems. And I don't remember any of it. I slept through it. So it's okay.   Howard Brown  57:46 Great. So the prep is the worst part. Isn't it though? The preps no fun. But the 20 minutes they have you under light anesthesia, they snipped the polyps and away you go and you keep living your life. So that's what I hope for everyone, because I will tell you, Michael, showing through the amount of chemotherapy, the amount of surgeries and the amount of side effects that I have is, is I don't wish that on anyone. I don't wish on anyone. It's not a good existence. It's hard. And quite frankly, it's, I want to prevent about it. And I'm just not talking about colon cancer, get your mammogram for breast cancer, get your check for prostate cancer, you know, self care is vital, because you can't have fun, do your job, work Grow family, if your hell if you're not healthy, and the emotional stuff they call the chemo brain or brain fog and or military personnel refer to it as PTSD. It's real. And you've got to be able to understand that, you know, coming from a cancer diagnosis is a transition. And I'll never forget that my two experiences and I I've got to build and move forward though. Because otherwise it gets dark, it gets lonely, it gets depressing, and then other things start to break down the parts don't work well. So I've chosen to find my happy place on the basketball court be very active in sounding the alarm for as an advocate. And as I never planned on being a book author and now I'm going to be a published author this summer. So there's good things that have come in my life. I've had a very interesting, interesting life. And we're here talking about it now so I appreciate it.   Michael Hingson  59:20 Well tell me about you in basketball seems to be your happy place.   Howard Brown  59:24 So everyone needs to find a happy place. I'll tell you why. The basketball court I've been playing since I was six years old and I was pretty good you know, I'm not gonna go professional. But I happen to like the team sport and I'm a point guard so I'm basically telling people what to do and trash talk and and all that. But I love it a

This episode features Dr. Mohamedtaki Tejani, Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Here, he explains three clinical trials underway at AdventHealth to evaluate the effectiveness and impact of different types of ctDNA testing for colorectal cancer patients. Circulating tumor DNA (ctDNA) is a sequencing technology that can detect very small amounts of tumor DNA in the body's circulatory system via a blood draw and specialized assay.

1. 'RHOA' Alum Cynthia Bailey & Husband Split (TMZ) 2. 'Glee' Controversies Explored in Discovery+ Docuseries From Ample Entertainment (Deadline) 3. Anne Hathaway Says Her 'Devil Wears Prada Look' at NYFW Was an 'Accident': 'It Was Kind of Nuts' (PEOPLE) 4. Heidi Klum and daughter Leni, 18, slammed for 'weird' and 'disturbing' lingerie ad (NY Post) 5. 'RHOBH' star Lisa Rinna slammed by Cancer Institute over finale comments (Page Six) The Toast with Jackie (@JackieOshry) and Claudia Oshry (@girlwithnojob)  NLOG Tickets: https://www.girlwithnojob.com/tour Merch: https://www.shopmorningtoast.com/ The Toast Patreon: https://www.patreon.com/themorningtoast Girl With No Job by Claudia Oshry: https://www.girlwithnojob.com/book

Videos: Dr. Ryan Cole: Covid Vaccine Side Effects Are Like A Nuclear Bomb New Rule: F*** tha Casting Police | Real Time with Bill Maher (HBO) Renters In America Are Running Out Of Options   Consuming green vegetables, supplements suppresses inflammatory bowel disease Sichuan University in China and from Cedars Sinai Medical Center, August 17, 2022 The dietary supplement chlorophyllin alleviates inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, according to researchers from the Center for Diabetes and Metabolism Research at Sichuan University in China and from Cedars Sinai Medical Center in Los Angeles. In addition, chlorophyllin significantly reduces mortality related to IBD, weight loss, diarrhea and hidden blood in the stool, intestinal epithelial damage and infiltration of inflammatory cells. The findings are published ahead of print in the American Journal of Physiology-Gastrointestinal and Liver Physiology, and the study has been chosen as an APS select article for August. Current therapeutics for IBD include medications that suppress the immune system (immunosuppressants) and surgery. However, long-term use of immunosuppressive treatments could result in severe adverse effects, including opportunistic infections and even organ failure. In this study, researchers found taking an oral chlorophyllin supplement—a compound derived from the green pigment found in plants—reduced colitis and abnormalities in the intestinal epithelia of mice. Also, consumption of green vegetables and chlorophyllin may be helpful for IBD recovery, in part through alleviation of inflammation and autolysosomal flux (a process that uses lysosome to degrade and remove toxic molecules and organelles). Green pigment found in these foods and supplements can initiate a feeding signaling to modulate autophagy in the cells, which suppresses IBD symptoms. (next) Coriander is a potent weapon against antibiotic resistant bacteria University of Beira Interior (Portugal) August 10, 2022 The problem of antibiotic resistant bacteria has been deemed a public health crisis, with the Centers for Disease Control and Prevention (CDC) reporting that invasive MRSA – or methicillin-resistant S. aureus – infections affect 80,000 people globally a year, and claim over 11,000 lives. But, what the CDC will never tell you is how coriander can potentially save lives. Researchers in Portugal now say that that the oil from coriander – a common kitchen spice – is quite toxic to a wide range of harmful bacteria, leading to hopes that it may be enlisted in the fight against MRSA and other pathogens. The scientific research about coriander is promising Researchers at University of Beira Interior used flow cytometry to study the effects of coriander oil on 12 different disease-causing types of bacteria, including E. coli, Salmonella, B. cereus and MRSA. In the study, published in Journal of Medical Microbiology, the oil significantly inhibited bacterial growth – especially that of MRSA and E. coli. (next) Tumour blood supply stopped in its tracks by modified natural compound University of New South Wales (Australia), August 10, 2022 Researchers have discovered how the modified natural compound dextran-catechin disrupts formation of blood vessels that fuel growth in the childhood cancer neuroblastoma. Researchers have discovered how a modified natural compound disrupts angiogenesis, the formation of blood vessel networks, in neuroblastoma tumours, stopping them laying down the vital supply lines that fuel cancer growth and spread. Dextran catechin is a sugar based conjugated form of catechin commonly found in green tea, red wine, dark chocolate and apple peels. Lead author Dr Orazio Vittorio of Children's Cancer Institute found that the natural polyphenol catechin slows tumour growth in the laboratory but breaks down too quickly in the body to be effective. (next) Researchers discover how DDT exposure contributes to Alzheimer's disease risk Florida International University and Rutgers University, August 17, 2022 A new study led by researchers from Florida International University and Rutgers reveals a mechanism linking the pesticide DDT to Alzheimer's disease. Published in Environmental Health Perspectives, the study shows how the persistent environmental pollutant DDT causes increased amounts of toxic amyloid beta, which form the characteristic amyloid plaques found in the brains of those with Alzheimer's disease. According to Jason Richardson, professor at FIU's Robert Stempel College of Public Health & Social Work and corresponding author, the study further demonstrates that DDT is an environmental risk factor for Alzheimer's disease.”The vast majority of research on the disease has been on genetics—and genetics are very important—but the genes that actually cause the disease are very rare,” Richardson says. “Environmental risk factors like exposure to DDT are modifiable. So, if we understand how DDT affects the brain, then perhaps we could target those mechanisms and help the people who have been highly exposed.” The study focused on sodium channels, which the nervous system uses to communicate between brain cells (neurons), as the potential mechanism. DDT causes these channels to remain open, leading to increased firing of neurons and increased release of amyloid-beta peptides. In the study, researchers demonstrate that if neurons are treated with tetrodotoxin, a compound that blocks sodium channels in the brain, the increased production of the amyloid precursor protein and toxic amyloid-beta species is prevented. “This finding could potentially provide a roadmap to future therapies for people highly exposed to DDT,” Richardson says. (next) Study shows how food preservatives may disrupt human hormones and promote obesity Cedars-Sinai Medicine Institute, August 9, 2022 Can chemicals that are added to breakfast cereals and other everyday products make you obese? Growing evidence from animal experiments suggests the answer may be “yes.” But confirming these findings in humans has faced formidable obstacles – until now. A new study published in Nature Communications details how Cedars-Sinai investigators developed a novel platform and protocol for testing the effects of chemicals known as endocrine disruptors on humans. The three chemicals tested in this study are abundant in modern life. Butylhydroxytoluene (BHT) is an antioxidant commonly added to breakfast cereals and other foods to protect nutrients and keep fats from turning rancid; perfluorooctanoic acid (PFOA) is a polymer found in some cookware, carpeting and other products; and tributyltin (TBT) is a compound in paints that can make its way into water and accumulate in seafood. The investigators used hormone-producing tissues grown from human stem cells to demonstrate how chronic exposure to these chemicals can interfere with signals sent from the digestive system to the brain that let people know when they are “full” during meals. When this signaling system breaks down, people often may continue eating, causing them to gain weight. (next) Standing desks can improve well-being, reduce stress among office workers University of Leicester (UK), August 17 2022 Standing desks can improve workers' performance as well as cut their time sitting by an hour each day, according to new research. Study authors add that getting up from an office chair also boosts well-being and energy levels, while reducing stress. “High levels of sitting time are associated with several health related outcomes and premature mortality, with high levels of workplace sitting associated with low vigor and job performance and high levels of presenteeism.” Presenteeism is the practice of being present at one's place of work for more hours than is required, especially as a manifestation of insecurity about one's job. Sedentary lifestyles increase the risk of chronic conditions including cardiovascular disease, type 2 diabetes, depression, anxiety, and cancer.